



# EDISON



## Edison Healthcare Insight

---

February 2019

Published by Edison Investment Research

**Maxim Jacobs**



Max joined Edison's healthcare team in December 2014. Prior to this he worked as a senior analyst at Guidepoint Global. Max has also previously worked as a senior analyst at Ridgemark Capital, a sector head at Broadfin Capital and as a senior analyst at Mehta Partners. He is a CFA charter holder.

**Dr Nathaniel Calloway**



Nathaniel Calloway joined the healthcare team in December 2015. Before Edison, he performed healthcare investment research for a fund at Bishop Rosen and for Wainscott Capital Partners. Prior to his role as an analyst he performed molecular neuroscience research at Cornell Medical School and holds a PhD in chemistry from Cornell. He has published eight scientific papers on topics ranging from physical chemistry to immunology, and he has been recognised as an American Heart Association fellow and an American Chemical Society Medicinal Chemistry fellow.

**Pooya Hemami**



Pooya is a licensed optometrist with over five years of experience in life sciences equity research. Prior to joining Edison, he covered the Canadian healthcare sector as a research analyst at Desjardins Capital Markets. He holds a doctor of optometry degree from the University of Montreal, and an MBA (finance concentration) from McGill University. He received his CFA charter in 2011.

**Dr John Savin**



John is an analyst working on biotech, pharma, medical device and diagnostics companies. As founder CEO of Physiomics, he devised the strategy, raised funds and took the company to AIM in 2004. At Greig Middleton, John was director in charge of the pharma and biotech analyst team and worked with corporate finance on fund-raising, IPOs and corporate restructuring. He has an industry background in sales and marketing with GE Healthcare and AstraZeneca and is a co-author on a number of scientific publications.

**Briana Warschun**



Briana received her Master of Science in Biomedical Engineering from Brown University in May 2017. Before that, she received a BS in Biomedical Engineering with a minor in Biophysics from George Washington University. While pursuing her education, Briana gained work experience through internships at the medtech behemoth C.R. Bard as well as at the healthcare consulting firm The Advisory Board Company.

**Dr Dennis Hulme**



Dennis joined Edison in December 2014. Prior to this he worked as an analyst at BBY Stockbrokers and as a research scientist at CSIRO. Dennis was ranked number two healthcare stock picker in the 2010 Starline Analyst Awards and has a PhD in veterinary sciences.

**Dr Jonas Peciulis**



Jonas joined Edison in November 2015. He is a qualified medical doctor with several years of clinical practice. He then moved into equity research as a healthcare analyst at Norne Securities, focused on Norwegian companies, and received two StarMine awards for stock picking in 2013. Most recently, he worked for a London-based life sciences venture capital company before completing his MBA degree.

**Dr Susie Jana**



Susie joined the team in September 2015 and has 16 years' experience in the healthcare sector. She is a qualified medical doctor, having studied medicine at UCL. She also holds an intercalated BSc in psychology. After a few years working as a junior doctor in the NHS, Susie joined the investment banking industry for six years on the sell-side covering biotechnology stocks, then mid- to large-cap pharmaceuticals at Société Générale. Most recently she worked as a buy-side analyst, covering European biotech, pharma and medtech stocks at F&C Investments for five years.

**Dr Andy Smith**



Andy joined the Healthcare team at Edison in November 2017 after a period as a senior principal in ICON's Pricing & Market Access consultancy. Prior to ICON he was chief investment officer at Mann Bioinvest and managed healthcare and biotech funds at AXA Framlington, SV Life Sciences, Schroders and 3i Group. Andy is a scientist by training and completed his PhD with Glaxochem after working for ICI and in the NHS. Between working as a lecturer at Guy's Medical School, he worked in R&D management at SmithKline Beecham, before moving to the Strategic Product Development group in SB Pharmaceuticals to be a global product manager. Andy also has an MBA from the University of Greenwich and teaches the finance module on the Master's in Bioscience Enterprise course at the University of Cambridge.

**Dr Daniel Wilkinson**



Daniel joined Edison's Healthcare team in January 2016. He spent four years at Imperial College London, where he undertook both a Master's in Chemical Biology of Health & Disease and a PhD in Biosensors and Biotechnology in Diabetes. Before this he worked at eTect, a spin-out company from the University of Leeds that was focused on biosensor technology. He is currently studying for the Investment Management Certificate (IMC).

**Alice Nettleton**



Alice joined Edison's Healthcare team in November 2017. Previously, she worked as a business analyst at PharmaVentures on a variety of consulting projects relating to life science transactions. Alice holds a BSc in Biomedical Sciences from King's College London and an MSc in Business Creation and Innovation in Biomedicine from Gothenburg University, and while studying has completed two internships at IP Pragmatics.

**Sean Conroy**



Sean joined Edison's healthcare team in September 2018. Previously, he worked at Charles River Laboratories performing drug discovery services. He holds a PhD in Medicinal Chemistry from the University of Nottingham.

## Contents

Company profiles	3
Company coverage	35

Prices at 15 February 2019

Published 21 February 2019

Welcome to the February edition of the Edison Healthcare Insight. In this edition we have profiled 63 of our healthcare companies under coverage.

Readers wishing more detail should visit our website, where reports are freely available for download ([www.edisongroup.com](http://www.edisongroup.com)). All profit and earnings figures shown are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison is a registered investment adviser regulated by the state of New York.

We welcome any [comments/suggestions](#) our readers may have.

**Neil Shah & Maxim Jacobs**

**Healthcare Research**

## Company profiles

---

Prices at 15 February

*US\$/£ exchange rate: 0.7796*

*€/£ exchange rate: 0.8795*

*C\$/£ exchange rate: 0.5873*

*A\$/£ exchange rate: 0.5539*

*NZ\$/£ exchange rate: 0.5325*

*SEK/£ exchange rate: 0.0840*

*DKK/£ exchange rate: 0.1179*

*NOK/£ exchange rate: 0.0901*

*JPY/£ exchange rate: 0.0070*

*NIS/£ exchange rate: 0.2100*

*CHF/£ exchange rate: 0.7740*

**Sector: Pharma & healthcare**

Price: €1.47  
 Market cap: €78m  
 Market: Euronext Brussels

**Share price graph (€)**

**Company description**

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients. Its main product, BARHEMSYS, is for the treatment of PONV and is forecast to launch in 2019.

**Price performance**

%	1m	3m	12m
Actual	(5.2)	(33.8)	N/A
Relative*	(9.0)	(34.6)	N/A

\* % Relative to local index

**Analyst**

Dr Daniel Wilkinson

## Acacia Pharma (ACPH)

**INVESTMENT SUMMARY**

Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia's lead product BARHEMSYS (repurposed amisulpride for the management of PONV) has been resubmitted to the FDA following receipt of a CRL (in October) relating to deficiencies at the contract manufacturer. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal to review the class 2 resubmission by 5 May 2019, but we highlight this could be delayed by the US government shutdown. We still anticipate a US launch of BARHEMSYS in Q2'19 for PONV 'rescue treatment' and expect broadening of use for PONV prophylaxis in subsequent years. As of 30 September, Acacia had net cash of £27.1m.

**INDUSTRY OUTLOOK**

Inadequately treated PONV leads to prolonged stay in post-anaesthesia care unit (PACU) recovery rooms. BARHEMSYS use could reduce patient hospitalisation time and the associated costs.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.0	(14.4)	(16.3)	(5.06)	N/A	N/A
2017	0.0	(3.0)	(6.5)	(2.32)	N/A	N/A
2018e	0.0	(16.7)	(18.4)	(0.33)	N/A	N/A
2019e	2.6	(42.7)	(45.1)	(0.81)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK4.70  
 Market cap: SEK108m  
 Market: NASDAQ OMX First North

**Share price graph (SEK)**

**Company description**

Acarix, a Swedish company, sells the CE-marked CADScor to enable about half of the patients to be ruled out from further, expensive testing. Private sales in Germany have started. Full EU sales may start in late 2019. US sales might start from 2022.

**Price performance**

%	1m	3m	12m
Actual	(7.1)	(36.5)	(52.9)
Relative*	(13.8)	(40.5)	(54.9)

\* % Relative to local index

**Analyst**

Dr John Savin

## Acarix (ACARIX)

**INVESTMENT SUMMARY**

Acarix has announced that imminent rule changes will delay potential German public reimbursement to at least 2020. The company has filed an application to maintain momentum and will build private sales in 2019. Full year 2018 results are due on 20 February. In the nine months to September, 15 systems and 1,480 patches were sold, giving SEK815k in sales and gross profit of SEK575k. Cash was SEK73.9m.


**INDUSTRY OUTLOOK**

CADScor helps doctors to identify cardiac patients, 97% of whom require no further risky invasive clinical testing. Acarix has positive feedback from private German users. A strategic alliance with MED will help sales in Germany. The Dan-NICAD II study evaluates the test in patients aged 30–39 with suspected stable coronary artery disease to aid key opinion leader acceptance of CADScor. The Seismo study explores the use of CADScor for the early diagnosis of heart failure. A US trial and sales are crucial for value development.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	N/A	(26.8)	(26.8)	(183.01)	N/A	N/A
2017	0.6	(29.2)	(30.7)	(129.31)	N/A	N/A
2018e	1.3	(40.2)	(42.5)	(184.55)	N/A	N/A
2019e	3.8	(57.3)	(59.8)	(259.68)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €2.04  
Market cap: €80m  
Market: MAB

**Share price graph (€)**

**Company description**

Based in Spain, ADL Bionatur Solutions provides contract manufacturing of fermentation-based biochem products and antibiotics, and develops and licenses its own portfolio of OTC and prescription animal health products, including probiotics and vaccines.

**Price performance**

%	1m	3m	12m
Actual	(4.7)	22.9	(5.6)
Relative*	(7.5)	22.2	0.6

\* % Relative to local index

**Analyst**

Pooya Hemami

## ADL Bionatur Solutions (BNT)

**INVESTMENT SUMMARY**

ADL Bionatur Solutions (ADL-BS) provides contract manufacturing of fermentation-based biochem products and antibiotics, and also develops and licenses its own portfolio of OTC and prescription animal health products, including probiotics and vaccines. ADL will have 2,400m<sup>3</sup> of total fermentation capacity available by mid-2019. While this operated at c 40% utilisation in H118, given recent contract wins and the ramping up in 2019 of two largest contracts (a six-year €146m flucosil-lactose deal and an arrangement with Amyris), ADL-BS expects to have 85% of capacity in use by year end 2019. This should drive it to firmly positive company-wide EBITDA and profitability in 2019.

**INDUSTRY OUTLOOK**

We estimate the ADL unit's solid pipeline of existing CMO contracts will contribute to the unit's generation of at least €55m in 2019 revenue (vs €12m in 2017). ADL-BS reported H118 net debt of €41.2m, and we estimate year-end 2018 net debt of approximately €45.4m (including a €7.0m loan from its majority shareholder).

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	14.6	(10.4)	(13.7)	(64.2)	N/A	N/A
2018e	27.8	(9.2)	(13.3)	(35.5)	N/A	47.5
2019e	64.8	5.7	1.2	3.1	65.8	N/A

**Sector: Pharma & healthcare**

Price: NZ\$2.05  
Market cap: NZ\$199m  
Market: NZSX

**Share price graph (NZ\$)**

**Company description**

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company's product portfolio includes prescription and over-the-counter drugs to treat a range of conditions and a proprietary nebuliser.

**Price performance**

%	1m	3m	12m
Actual	(4.7)	(8.9)	(10.9)
Relative*	(7.6)	(12.7)	(19.5)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## AFT Pharmaceuticals (AFT)

**INVESTMENT SUMMARY**

AFT Pharmaceuticals is a New Zealand-based specialty pharmaceutical company that currently sells 130 prescription specialty generics and OTC products through its own sales force in New Zealand, Australia and South-East Asia and has been expanding its geographic footprint. Maxigesic, its combination acetaminophen/ibuprofen product addressing a \$10.4b market, is currently sold and launched in 15 countries with distribution agreements in place in a total of 128. Additionally, AFT is expecting its first approval for Maxigesic IV in mid-2019, is preparing to file in multiple countries, with a filing in the US expected by the end of calendar 2019. AFT is also developing a handheld device called SURF Nebuliser, which is able to deliver therapies intranasally, with a main focus on the \$3 billion conscious sedation market.

**INDUSTRY OUTLOOK**

AFT is a multi product company targeting pharmacy prescription, OTC and hospital markets. Data for Maxigesic offers them a competitive advantage in a fragmented industry.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	69.2	(15.1)	(18.5)	(19.12)	N/A	N/A
2018	80.1	(10.5)	(12.9)	(13.30)	N/A	N/A
2019e	91.2	1.6	(2.2)	(2.20)	N/A	262.1
2020e	109.5	11.9	10.0	10.31	19.9	21.8



**Sector: Pharma & healthcare**

Price: €1.12  
 Market cap: €22m  
 Market: Euronext Brussels

**Share price graph (€)**



**Company description**

ASIT biotech is a clinical-stage company focused on developing therapies for allergies. It uses its proprietary ASIT+ technology platform to develop products containing highly purified allergen fragments in an adjuvant-free formulation, selected to be safe while maintaining the capacity to stimulate the immune system.

**Price performance**

%	1m	3m	12m
Actual	(20.0)	(36.0)	(74.0)
Relative*	(23.3)	(36.7)	(71.5)

\* % Relative to local index

**Analyst**

Andy Smith

## ASIT biotech (ASIT)

**INVESTMENT SUMMARY**

ASIT Biotech's ASIT+ short-course allergy immunotherapy (AIT) platform has generated a Phase III drug for the prevention of grass pollen allergy and earlier-stage programs in house dust mite (hdm-ASIT+) and in peanut allergies (pnt-ASIT+). Unlike most other AITs (subcutaneous or sublingual), ASIT's products only require four injections before the allergy season. The second Phase III study for gp-ASIT+ has started and results are expected after the pollen season of 2019. We expect ASIT Biotech to self-market gp-ASIT+ in Europe and outlicense all other rights in ex-Europe. ASIT recently raised money to fully-fund its clinical programs.

**INDUSTRY OUTLOOK**

Although grass pollen and house dust mite allergies are not life-threatening in most cases, they result in a significant symptom burden for affected patients. With a safe and effective four-dose regimen, ASIT could expect some usage in the less-severe segment where currently a regimen of many doses does not balance the risk-benefit.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(12.3)	(12.3)	(110.00)	N/A	N/A
2017	0.0	(12.0)	(12.0)	(93.60)	N/A	N/A
2018e	0.0	(13.3)	(13.3)	(81.89)	N/A	N/A
2019e	0.0	(15.6)	(15.5)	(88.44)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$1.51  
 Market cap: US\$9m  
 Market: NASDAQ

**Share price graph (US\$)**



**Company description**

Based in Seattle, WA, Atossa Genetics is focused on the development of locally administered pharmaceuticals for the treatment of pre-cancer and early-stage breast cancer. Lead candidate afimoxigene topical gel is expected to start a Phase II study in 2016 in breast hyperplasia or DCIS.

**Price performance**

%	1m	3m	12m
Actual	19.8	15.3	(81.8)
Relative*	12.7	13.4	(82.1)

\* % Relative to local index

**Analyst**

Pooya Hemami

## Atossa Genetics (ATOS)

**INVESTMENT SUMMARY**

Atossa is advancing endoxifen, a metabolite of tamoxifen, as a topical treatment for high mammographic breast density (MBD), a condition associated with higher cancer risk and gynecomastia. Atossa is also developing oral endoxifen as a potential treatment for breast cancer patients refractory to tamoxifen. About 20-25% of the 1.0m women taking tamoxifen worldwide develop resistance to it, and have an increased risk for cancer recurrence. The firm reported positive Phase I data for both formulations, including results showing that patients obtain "steady state" serum endoxifen levels after about 7 days of daily oral dosing.

**INDUSTRY OUTLOOK**

Atossa started Phase II trials for oral and topical endoxifen in women, and completed enrollment for the topical study. It is also planning to start a Phase II study in men with gynecomastia. It also started preclinical studies with its IDMC to explore potential use in immunotherapy. Atossa reported \$13.0m net cash on 30 September 2018, which we believe can sustain operations until early 2020.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(6.9)	(7.3)	(2951.72)	N/A	N/A
2017	0.0	(7.1)	(7.2)	(1000.81)	N/A	N/A
2018e	0.0	(12.9)	(12.9)	(430.82)	N/A	N/A
2019e	0.0	(11.7)	(11.7)	(188.22)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$0.37  
 Market cap: US\$14m  
 Market: NASDAQ

**Share price graph (US\$)**



**Company description**

Auris Medical is a Swiss biopharmaceutical company developing neurology therapeutics. The company is developing intranasal betahistine in a Phase I trial for mental disorder supportive care and is entering Phase II for vertigo; both are designed to demonstrate proof-of-concept.

**Price performance**

%	1m	3m	12m
Actual	(19.8)	(39.9)	(87.2)
Relative*	(24.6)	(40.9)	(87.4)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Auris Medical Holding (EARS)

**INVESTMENT SUMMARY**

Auris Medical is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The company's primary focus is on the development of AM-125 (intranasal betahistine) for the treatment of acute vertigo. Oral betahistine dihydrochloride has been prescribed in Europe for decades for all types of vertigo, with an average 26% market share but is not available in the US. Following positive Phase I data where their formulation demonstrated superior bioavailability to the oral version, Auris expects to initiate its Phase II clinical trial in 138 patients with surgically-induced acute vertigo in Q119. Auris is also developing AM-201, an intranasal betahistine formulation, for co-administration with olanzapine to counteract adverse effects, especially weight gain.

**INDUSTRY OUTLOOK**

Acute vertigo/dizziness is one of the most common causes of visits to the emergency room with roughly 2.6m visits associated with the condition each year.

Y/E Dec	Revenue (CHFm)	EBITDA (CHFm)	PBT (CHFm)	EPS (CHFc)	P/E (x)	P/CF (x)
2016	0.0	(30.3)	(31.0)	(89.87)	N/A	N/A
2017	0.0	(24.5)	(25.9)	(53.60)	N/A	N/A
2018e	0.0	(11.7)	(12.7)	(41.58)	N/A	N/A
2019e	0.0	(11.4)	(11.8)	(30.78)	N/A	N/A

**Sector: Pharma & healthcare**

Price: CHF50.65  
 Market cap: CHF602m  
 Market: Swiss Stock Exchange

**Share price graph (CHF)**



**Company description**

Basilea focuses on anti-infectives and oncology. Lead products are Cresemba (an antifungal), which is approved in the US and Europe, and Zevtera (an anti-MRSA broad-spectrum antibiotic), approved in many European and non-European countries for pneumonia.

**Price performance**

%	1m	3m	12m
Actual	(1.8)	9.2	(26.3)
Relative*	(6.3)	4.8	(28.9)

\* % Relative to local index

**Analyst**

Dr Susie Jana

## Basilea Pharmaceutica (BSLN)

**INVESTMENT SUMMARY**

Basilea has two approved hospital-based products: Cresemba (severe mold infections) and Zevtera (bacterial infections). Multiple licensing/distribution agreements are in place for Cresemba and Zevtera, which should drive top-line growth; revenues from these anti-infectives were up 56% y-o-y (FY18 CHF82m) and in February a \$5m milestone was triggered from Pfizer, which markets Cresemba in Europe (ex Nordics), Russia, Turkey, Israel, China and Asia-Pacific. US Phase III registration trials have initiated for Zevtera in ABSSSI (top line H219) and in SAB (top line H221); both are required for a US FDA submission. Basilea's oncology pipeline is spearheaded by in-licensed asset derazantinib (pan-FGFR inhibitor), which is in a Phase II registration study for intrahepatic cholangiocarcinoma that reported promising interim data in January. A Phase I/II study combining derazantinib with Roche's PD-L1 antibody atezolizumab (Tecentriq) in patients with advanced urothelial cancer is expected to initiate mid-2019.

**INDUSTRY OUTLOOK**


There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA), fungus or cancer. Hence, the opportunities for Zevtera, Cresemba and Basilea's oncology pipeline could be significant.

Y/E Dec	Revenue (CHFm)	EBITDA (CHFm)	PBT (CHFm)	EPS (fd) (CHFc)	P/E (x)	P/CF (x)
2016	66.0	(41.6)	(50.9)	(505.74)	N/A	N/A
2017	101.5	(12.2)	(18.9)	(178.36)	N/A	28.8
2018e	124.0	(21.9)	(29.6)	(274.34)	N/A	N/A
2019e	137.3	(18.8)	(26.7)	(247.83)	N/A	N/A



**Sector: Pharma & healthcare**

Price: DKK3.96  
 Market cap: DKK656m  
 Market: NASDAQ OMX (CPH)

**Share price graph (DKK)**

**Company description**

BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.

**Price performance**

%	1m	3m	12m
Actual	2.6	2.5	11.2
Relative*	(3.5)	(4.6)	11.7

\* % Relative to local index

**Analyst**

Dr Nathaniel Calloway

## BioPorto Diagnostics (BIOPOR)

**INVESTMENT SUMMARY**

BioPorto's lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The test is currently completing pivotal clinical trials for adults in plasma and for children in urine. Two 510(k)'s will be submitted to the FDA for approval in 2019. The NGAL test is commercially available for research purposes in the US and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.

**INDUSTRY OUTLOOK**

The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.

Y/E Dec	Revenue (DKKm)	EBITDA (DKKm)	PBT (DKKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	20.7	(22.6)	(22.4)	(157.0)	N/A	N/A
2017	25.2	(33.1)	(33.7)	(203.0)	N/A	N/A
2018e	29.6	(37.6)	(37.2)	(209.0)	N/A	N/A
2019e	34.7	(17.7)	(17.0)	(91.0)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK20.00  
 Market cap: SEK1035m  
 Market: OMX

**Share price graph (SEK)**

**Company description**

BONESUPPORT is an orthobiologics company that has commercialised three synthetic bone graft substitutes and has several other projects in R&D. The marketed products, CERAMENT BVF, CERAMENT G (gentamicin) and CERAMENT V (vancomycin), are intended to help orthopaedic surgeons manage bone voids and defects after injuries or diseases affecting bones.

**Price performance**

%	1m	3m	12m
Actual	0.0	2.6	14.3
Relative*	(7.1)	(3.9)	9.5

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## BONESUPPORT (BONEX)

**INVESTMENT SUMMARY**

BONESUPPORT's investment case rests on three strategic pillars: effective commercial organisation, products backed by clinical data and R&D innovation. The company is selling CERAMENT bone void filler (BVF) in the US and Europe, and two antibiotic-eluting BVF products CERAMENT G/V in Europe. BONESUPPORT terminated its agreement with its exclusive distributor in the US and has since signed up more than 30 distributors in its own independent network to promote CERAMENT BVF in the US. The company recently signed agreements with MTF Biologics and Collagen Matrix to grow its product offering sold through its US platform, and plans to drive sales in trauma. After a successful IPO in June 2017 raising SEK520m, the company is well funded.

**INDUSTRY OUTLOOK**

Innovation is one of the key strategic directions for BONESUPPORT to differentiate its products from competitors offering commodity-like bone graft substitutes. The company has gathered data and is undertaking clinical trials to support the claims of its marketed products.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	104.6	(87.4)	(108.4)	(422.06)	N/A	N/A
2017	129.3	(97.9)	(126.7)	(320.78)	N/A	N/A
2018e	103.8	(174.4)	(174.3)	(344.22)	N/A	N/A
2019e	213.8	(140.9)	(141.0)	(272.11)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK12.76  
 Market cap: SEK952m  
 Market NASDAQ OMX First North

**Share price graph (SEK)**

**Company description**

Brighter is a Swedish healthtech company focused on the development and commercialisation of self-monitoring and self-treatment health solutions for diabetes.

**Price performance**

%	1m	3m	12m
Actual	53.4	16.8	53.9
Relative*	42.4	9.5	47.5

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Brighter (BRIG)

**INVESTMENT SUMMARY**

Brighter is a healthtech company developing solutions for chronic diseases. Its initial strategy is the launch of Actiste, a mobile-connected glucose meter and insulin injection device for diabetes. Brighter's Actiste integrates three essential steps for daily diabetes management into one device: a blood glucose meter, a lancing device and insulin injection apparatus. By reducing the number of treatment steps to nine from 28 in comparison to traditional self-blood glucose (SMBG) meters, Brighter's goal is to promote patient adherence and concordance to daily insulin-dependent diabetes management in an effort to reduce complications associated with poor self-care.

**INDUSTRY OUTLOOK**

In 2017, costs attributed to diagnosed diabetes and associated complications, such as cardiovascular disease and nephropathy, totalled \$327bn in the US. Patient opinions of treatment burden are heavily correlated with adherence to self-care.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	3.3	(17.3)	(18.7)	(23.53)	N/A	N/A
2017	1.4	(19.7)	(22.8)	(42.01)	N/A	N/A
2018e	2.1	(30.0)	(33.8)	(51.32)	N/A	N/A
2019e	9.2	(49.4)	(53.5)	(75.49)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK14.80  
 Market cap: SEK980m  
 Market NASDAQ OMX First North

**Share price graph (SEK)**

**Company description**

Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer.

**Price performance**

%	1m	3m	12m
Actual	(1.3)	(2.6)	110.2
Relative*	(8.4)	(8.7)	101.4

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## Cantargia (CANT)

**INVESTMENT SUMMARY**

Cantargia is developing two antibodies against IL1RAP: Nidanilimab (CAN04) and CANxx. Nidanilimab is currently being studied in a Phase I/II CANFOUR trial where the Phase I part focuses on several solid tumours, and the Phase II part focuses on NSCLC and pancreatic cancer. So far, Nidanilimab was found to be safe and well tolerated in the Phase I part of the study, and the first patient has been treated in the Phase II part. Nidanilimab has a dual mechanism of action: inhibition of IL-1 signaling and antibody-dependent cellular cytotoxicity (ADCC). Novartis is conducting three Phase III trials in NSCLC with canakinumab (IL-1beta antibody) following some unexpected results from its six-year Phase III cardiovascular outcomes study in heart attack patients. Cantargia has recently up-listed to the Nasdaq Stockholm main market.

**INDUSTRY OUTLOOK**

Increasing the understanding of inflammation in malignant process now includes findings that cytokines are not only produced by the immune cells, but also cancer itself could produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent potentially promising class of targets in cancer management.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2016	0.0	(47.6)	(47.5)	(271.96)	N/A	N/A
2017	0.0	(60.0)	(60.3)	(186.00)	N/A	N/A
2018e	0.0	(88.5)	(86.0)	(152.06)	N/A	N/A
2019e	0.0	(93.8)	(93.5)	(141.19)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €22.05  
 Market cap: €204m  
 Market: Euronext Growth

**Share price graph (€)**

**Company description**

Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

**Price performance**

%	1m	3m	12m
Actual	(12.8)	4.5	2.3
Relative*	(18.7)	2.9	4.8

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Carmat (ALCAR)

**INVESTMENT SUMMARY**

Carmat is enrolling its 20-patient study for its artificial heart in France, Kazakhstan, the Czech Republic and Denmark. Data from the first cohort of 10 patients indicated that 70% of the patients within that cohort reached the primary endpoint of six-month survival with the bioprosthesis or a successful heart transplant within six months of the device implant. The second cohort of patients is being enrolled in the trial.

**INDUSTRY OUTLOOK**

The Carmat artificial heart is being developed as a permanent replacement or destination therapy for chronic biventricular heart failure or acute myocardial infarction patients who do not have access to a human donor heart. Despite the high EU and US prevalence of stage IV heart failure (c 500,000 patients), the shortfall in donor hearts is such that only about 3,800 human heart transplants were performed in Europe and the US in 2013.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.3	(24.1)	(25.7)	(379.73)	N/A	N/A
2017	0.0	(30.3)	(31.5)	(323.54)	N/A	N/A
2018e	0.7	(38.2)	(39.6)	(421.19)	N/A	N/A
2019e	0.0	(24.2)	(28.7)	(311.10)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$3.60  
 Market cap: US\$337m  
 Market: NASDAQ

**Share price graph (US\$)**

**Company description**

CASI is a pharmaceutical company that has acquired or licensed a series of drugs that it intends to market in China. These include proprietary drugs licensed from Spectrum Pharmaceuticals and a portfolio of ANDAs. The goal is to seek approval through new pathways that have been opened in the quickly changing Chinese regulatory environment.

**Price performance**

%	1m	3m	12m
Actual	(8.6)	2.3	(6.5)
Relative*	(14.1)	0.6	(8.0)

\* % Relative to local index

**Analyst**

Dr Nathaniel Calloway

## CASI Pharmaceuticals (CASI)

**INVESTMENT SUMMARY**

CASI has a multipronged approach to the entrance into the Chinese pharmaceutical market. It recently received approval for Evomela (melphalan) in China via the priority review pathway because it was the first approval in the country for any melphalan product. It also intends to establish manufacturing in China for select products from its portfolio of ANDAs, which should also expedite approval under the new regulatory regime.

**INDUSTRY OUTLOOK**

The Chinese regulatory authorities have made a series of substantial changes to their process for drug approval in recent years to improve the availability of new drugs. The Chinese National Medical Products Administration (NMPA, formerly the CFDA) has established new classes of applications for drugs that are previously approved outside of China. Additionally, there is a set of criteria for priority review, which can significantly reduce review times.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(6.4)	(6.5)	(11.56)	N/A	N/A
2017	0.0	(10.0)	(10.1)	(16.45)	N/A	N/A
2018e	0.0	(18.4)	(18.8)	(22.61)	N/A	N/A
2019e	10.9	(9.8)	(14.3)	(15.01)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$19.56  
 Market cap: US\$360m  
 Market: NASDAQ

**Share price graph (US\$)**

**Company description**

Cellular Biomedicine Group is a biotechnology company developing cell-based therapeutics with operations primarily in China.

**Price performance**

%	1m	3m	12m
Actual	8.5	12.9	9.3
Relative*	2.1	11.0	7.5

\* % Relative to local index

**Analyst**

Dr Nathaniel Calloway

## Cellular Biomedicine Group (CBMG)

**INVESTMENT SUMMARY**

Cellular Biomedicine Group (CBMG) is a trans-Pacific cell therapy company developing products in China and the US. It has signed an agreement with Novartis to manufacture the CAR-T therapy Kymriah for the Chinese market. It also has a series of internal CAR-T programs, which will be entering the clinic in late 2018 and 2019. Additionally, it is adapting its knee osteoarthritis (KOA) treatment ReJoin as an allogeneic product, AlloJoin, which recently completed Phase I testing.

**INDUSTRY OUTLOOK**

The company is focusing on advancing its CAR-T pipeline. The first CAR-T therapies were just recently approved in 2017 for the treatment of ALL and DLBCL, with developing ongoing in other hematologic malignancies such as multiple myeloma. Progress in the space has triggered significant M&A interest: Gilead bought Kite Pharma for \$12bn in August 2017, and Celgene has an outstanding tender offer for Juno Therapeutics at \$9bn.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	0.6	(15.7)	(18.1)	(134.30)	N/A	N/A
2017	0.3	(19.2)	(20.1)	(140.41)	N/A	N/A
2018e	0.1	(22.7)	(27.1)	(143.01)	N/A	N/A
2019e	5.3	(17.5)	(21.6)	(108.59)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €18.30  
 Market cap: €219m  
 Market: Euronext Brussels

**Share price graph (€)**

**Company description**

Celyad is developing an innovative Natural Killer Receptor CAR T-cell therapy (CYAD-01). This focuses on AML and metastatic colorectal cancer. A comprehensive set of clinical studies is underway.

**Price performance**

%	1m	3m	12m
Actual	(6.2)	(23.5)	(46.0)
Relative*	(10.0)	(24.4)	(40.8)

\* % Relative to local index

**Analyst**

Dr John Savin

## Celyad (CYAD)

**INVESTMENT SUMMARY**

Data in December confirmed that CYAD-01 T-cells can destroy acute myeloid leukaemia (AML) cells. CYAD-01 showed 62% (5/8) anti-leukemic activity across three dose levels including 38% (3/8) with some form of complete response; a further MDS CR is reported. Safety was excellent. Further data are promised in mid-19. Celyad is aiming to accelerate CYAD-01 development for the treatment of AML and MDS, and to initiate a Phase 2 trial in H2 2019. In solid cancers, a study combining CYAD-01 with preconditioning is underway and may be crucial. The alloSHRINK allogeneic (CYAD-101) trial in mCRC is underway. This gives Celyad the lead in mass-market allogeneic therapy for solid cancer. Celyad had €55.9m cash on 30 Sept.

**INDUSTRY OUTLOOK**

CAR T-cell therapeutics have seen low sales and shift in interest to bi-specific therapies.

There is still strong interest in allogeneic products, where Celyad holds a key patent. Celyad remains in a key position in both AML and mCRC with a strong programme in solid cancers.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	8.5	(21.2)	(20.0)	(209.0)	N/A	N/A
2017	3.5	(22.3)	(26.8)	(279.0)	N/A	N/A
2018e	0.0	(26.5)	(27.3)	(243.0)	N/A	N/A
2019e	0.0	(27.8)	(28.5)	(238.0)	N/A	N/A

**Sector: Pharma & healthcare**

Price: NIS2.92  
 Market cap: NIS471m  
 Market: TASE

**Share price graph (NIS)**

**Company description**

Clal Biotechnology Industries is a healthcare investment company focused on investing in a variety of therapeutic, diagnostic, and medical device companies covering a full range of development phases from preclinical to post-market.

**Price performance**

%	1m	3m	12m
Actual	8.3	(7.3)	(10.2)
Relative*	3.0	(4.5)	(14.8)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Clal Biotechnology (CBI)

**INVESTMENT SUMMARY**

Clal Biotechnology (CBI) is a healthcare investment company with an extensive portfolio incorporating a diverse range of technologies, indications and stages of development. CBI holds direct investments in 10 companies (nine biotech and one medical device company), most importantly MediWound, a NASDAQ-listed wound care company and Gamida Cell, which is developing a universal bone marrow transplant product and recently listed on the NASDAQ. Also, Anchiano and Biokine have programmes in Phase III or Phase III ready. The year 2019 has already proven to be eventful for CBI's investments with MediWound announcing a successful Phase III study for NexoBrid and Anchiano successfully listing on NASDAQ.

**INDUSTRY OUTLOOK**

CBI is invested in a variety of life science companies, including a wide and diverse range of technologies, indications and stages of development, all of which have high potential.

Y/E Dec	Revenue (NISm)	EBITDA (NISm)	PBT (NISm)	EPS (NIS)	P/E (x)	P/CF (x)
2016	30.5	(434.8)	(454.1)	(289.34)	N/A	N/A
2017	73.6	(103.3)	(54.2)	(15.02)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

**Sector: Pharma & healthcare**

Price: €1.50  
 Market cap: €23m  
 Market: Euronext Growth

**Share price graph (€)**

**Company description**

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

**Price performance**

%	1m	3m	12m
Actual	(10.7)	(26.5)	(32.1)
Relative*	(16.7)	(27.6)	(30.5)

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## Deinove (ALDEI)

**INVESTMENT SUMMARY**

FY18 has been a pivotal year for Deinove with the launch of two products in its cosmetic division and a number of deals. These include the acquisition of Morphochem's clinical-stage antibiotic DNV3837 (formerly MCB3837) and R&D collaboration agreements with Naicons, bioMérieux and Calibr. The launch of a second, internally developed carotenoid product is planned in 2019, while the initiation of the Phase II trial with DNV3837, expected later this year, will be a milestone R&D event. The company raised €8.5m in 2018 and renewed the equity line with Kepler Cheuvreux to enable it to launch a Phase II clinical trial for the Morphochem compound and finance its other activities. Our forecasts are under review.

**INDUSTRY OUTLOOK**

Environmentalism will underpin growth in green chemistry and growing antimicrobial resistance to current antibiotics will demand the discovery of new antibiotic structures.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.8	(6.4)	(7.7)	(72.6)	N/A	N/A
2017	0.2	(8.5)	(9.7)	(67.7)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A



**Sector: Pharma & healthcare**

Price: 83.0p  
Market cap: £36m  
Market: AIM

**Share price graph (p)**

**Company description**

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobial agents that have unique properties to improve outcomes for patients. Destiny's first product, XF-73, is about to start a US Phase IIb clinical study.

**Price performance**

%	1m	3m	12m
Actual	29.7	14.5	(40.3)
Relative*	24.0	11.7	(39.9)

\* % Relative to local index

**Analyst**

Andy Smith

## Destiny Pharma (DEST)

**INVESTMENT SUMMARY**

Destiny Pharma is a virtual UK antimicrobial discovery company in Phase II clinical studies in the US. Destiny's XF series of antimicrobial agents are novel, rapidly bactericidal and not associated with bacterial resistance, which typically limits the use of other antimicrobial agents. This makes Destiny's lead product, XF-73, ideal for the prevention of post-operative infections, an indication in which no other drugs have been approved. The activity of the XF-series against resistant bacteria may also have utility in the treatment of infections with a biofilm component like cystic fibrosis. We forecast Destiny's cash reach to at least 2020, with Phase IIb results for XF-73 available at the end of 2019.

**INDUSTRY OUTLOOK**

While there are valid commercial criticisms of antibiotic development, the growing problem of antimicrobial resistance is making non-dilutive and alternative funding methods available to make antimicrobial drug development easier on companies. In addition, resistance has not been observed against Destiny's agents and their new preventative indications make antibiotic stewardship less of an issue.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (fd) (p)	P/E (x)	P/CF (x)
2016	0.0	(1.3)	(1.5)	(3.94)	N/A	N/A
2017	0.0	(2.5)	(3.2)	(8.45)	N/A	N/A
2018e	0.0	(6.8)	(7.4)	(14.28)	N/A	N/A
2019e	0.5	(8.3)	(8.3)	(15.29)	N/A	N/A

**Sector: Pharma & healthcare**

Price: 5.2p  
Market cap: £14m  
Market: AIM

**Share price graph (p)**

**Company description**

e-Therapeutics is a UK-based drug discovery company that has developed a proprietary network-driven drug discovery platform that has generated pre-clinical licensing opportunities.

**Price performance**

%	1m	3m	12m
Actual	(14.3)	(27.6)	(40.0)
Relative*	(18.0)	(29.4)	(39.6)

\* % Relative to local index

**Analyst**

Andy Smith

## e-Therapeutics (ETX)

**INVESTMENT SUMMARY**

e-Therapeutics (ETX) offers investors exposure to a proprietary, cutting-edge in silico network-driven drug discovery (NDD) platform that has already attracted significant investment and has been fully operational since 2014. This second-generation platform has generated two new chemical entities in immunoncology that are the subject of business development efforts and have achieved commercial validation through the deal with Novo Nordisk. ETX's priority is securing further partnerships to provide external validation and it has recently signed deals to enhance the NDD platform with AI and a discovery deal with C4XD. ETX's strength is in complex disease networks such as cancer.

**INDUSTRY OUTLOOK**

Network-driven approaches could revolutionise drug discovery and shorten the path to market by minimising technical risks and drug development costs. ETX is differentiated from its competitors through its expertise in curating, processing and analysing data in the context of the mechanistic modelling of disease.

Y/E Jan	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2017	0.0	(14.2)	(14.1)	(4.1)	N/A	N/A
2018	0.0	(6.7)	(6.7)	(2.0)	N/A	N/A
2019e	0.0	(5.0)	(5.1)	(1.4)	N/A	N/A
2020e	0.0	(4.0)	(4.0)	(1.1)	N/A	N/A



**Sector: Pharma & healthcare**

Price: NIS0.95  
 Market cap: NIS220m  
 Market: TASE

**Share price graph (NIS)**

**Company description**

Elbit Medical Technologies is an Israeli biomedical and healthcare technology group. Its portfolio of two companies is focused on medical devices and therapeutics: InSightec, which develops and markets the ExAblate platform for non-invasive thermal tissue ablation, and Gamida Cell, which is developing a universal bone marrow transplant.

**Price performance**

%	1m	3m	12m
Actual	0.0	(14.7)	(13.7)
Relative*	(4.9)	(12.1)	(18.1)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Elbit Medical Technologies (EMTC)

**INVESTMENT SUMMARY**

Elbit Medical Technologies is an Israel-based healthcare investment company. The company holds a ~22% (~18.5% fully diluted) stake in InSightec, a commercial-stage medical device company. InSightec's ExAblate uses MRI and high-intensity focused ultrasound to perform precise and incisionless thermal tissue ablation. ExAblate has achieved FDA and CE approval for three distinct indications, with revenues of \$32.1m for FY17. The company is also invested in Gamida Cell (~11%), which is developing NiCord, a product derived from umbilical cord blood (UCB) stem cells, for the treatment of high-risk haematological malignancies. Enrolment is underway for a Phase III study with enrolment expected to be complete in H219. Gamida Cell recently went public on the NASDAQ, raising \$53m.

**INDUSTRY OUTLOOK**

Elbit Medical Technologies is invested in the healthcare sector through its holdings in two companies that are developing medical device and therapeutic technologies.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(0.6)	(3.7)	0.0	N/A	N/A
2017	0.0	(0.7)	(5.2)	0.0	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

**Sector: Pharma & healthcare**

Price: €5.40  
 Market cap: €27m  
 Market: NASDAQ OMX Mid Cap

**Share price graph (€)**

**Company description**

Herantis Pharma is a Finnish innovative biopharmaceutical company focusing on regenerative medicines for unmet needs. Key assets include CDNF for Parkinson's disease and Lymfactin for breast cancer associated lymphedema.

**Price performance**

%	1m	3m	12m
Actual	5.9	(5.3)	(18.8)
Relative*	0.5	(9.6)	(18.2)

\* % Relative to local index

**Analyst**

Dr Susie Jana

## Herantis Pharma (HRTS)

**INVESTMENT SUMMARY**

Herantis Pharma's two lead assets are cerebral dopamine neurotrophic factor (CDNF), a potential disease-modifying treatment for Parkinson's disease (PD), and Lymfactin, the only gene therapy in development for breast cancer-related associated secondary lymphedema (BCAL). The underlying science for both is novel and positive efficacy/safety data from ongoing proof-of-concept clinical trials expected in 2019–20 would serve as validation of the research efforts and additionally could crystallise value through partnering opportunities for these unique assets.

**INDUSTRY OUTLOOK**

Herantis Pharma is focused on the development of innovative regenerative medicines targeting unmet needs. Key assets include CDNF for Parkinson's disease and Lymfactin for breast cancer associated lymphedema.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	N/A	(4.4)	(107.5)	N/A	N/A
2017	0.0	N/A	(0.1)	(3.2)	N/A	N/A
2018e	0.0	N/A	(3.2)	(64.5)	N/A	N/A
2019e	0.0	N/A	(3.4)	(68.2)	N/A	N/A

**Sector: Pharma & healthcare**

Price: 3885.0p  
 Market cap: £2590m  
 Market: AIM, NASDAQ

**Share price graph (p)**

**Company description**

Hutchison China MediTech (HCM) is an innovative China-based biopharma company targeting the global market for novel, highly selective oral oncology and immunology drugs. Its established China Healthcare business is growing ahead of the market. HCM is the healthcare arm of CK Hutchison (c 40% listed on AIM and NASDAQ).

**Price performance**

%	1m	3m	12m
Actual	15.6	(30.6)	(16.7)
Relative*	10.6	(32.3)	(16.2)

\* % Relative to local index

**Analyst**

Dr Susie Jana

## Hutchison China MediTech (HCM)

**INVESTMENT SUMMARY**

HCM has built a substantial pipeline of potentially first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, some of which are in development with strategic partners. Following China registration approval from the National Medicinal Products Administration of China for the treatment of CRC (3L), commercial marketing of fruquintinib (Elunate) commenced in November (through partner Eli Lilly). HCM has also announced several new partnerships and plans to combine its antiangiogenic TKIs (surufatinib and fruquintinib) with immune checkpoint inhibitors (PD-1 antibodies), with a view to developing a best-in-class combination therapy for the treatment of solid tumours. At 30 June, HCM had net cash of \$295.8m. After failing to reach the primary endpoint in the Phase III FALUCA trial, our valuation of HCM is under review.

**INDUSTRY OUTLOOK**

HCM's profitable Chinese healthcare business continues to benefit from the fast-growing domestic market, while the clinical, regulatory and technological environments are highly conducive to novel drug development. In the longer term, if the oncology and immunology pipeline comes to fruition we expect HCM to become a major China and international oncology company.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	216.1	(44.3)	(47.4)	19.6	255.4	N/A
2017	241.2	(50.7)	(53.5)	(43.3)	N/A	N/A
2018e	162.5	(94.8)	(99.5)	(109.5)	N/A	N/A
2019e	180.1	(113.9)	(120.1)	(139.4)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK8.20  
 Market cap: SEK585m  
 Market: OMX

**Share price graph (SEK)**

**Company description**

Immunicum is a clinical-stage immunoncology company based in Stockholm, Sweden. The company is developing an allogeneic dendritic cell immune primer for use in combination with tyrosine kinase inhibitors and checkpoint inhibitors in multiple solid tumour indications.

**Price performance**

%	1m	3m	12m
Actual	(15.5)	(4.8)	26.2
Relative*	(21.5)	(10.7)	20.9

\* % Relative to local index

**Analyst**

Andy Smith

## Immunicum (IMMU)

**INVESTMENT SUMMARY**

Immunicum is a NASDAQ Sweden-listed, clinical-stage immunoncology (IO) company that is developing allogeneic dendritic cell (DC) technologies. Its first clinical product, ilixadencel, is in Phase I and II combination studies in several solid tumour indications. Three studies are expected to render results in 2019. The first is the Phase II MERECA data in renal cell carcinoma (in combination with sunitinib). Interim data from the Phase I/II multi-indication ILIAD study where ilixadencel is being tested in combination with a checkpoint inhibitor (CPI) are also expected in H219 and Merck KgaA and Pfizer have entered into a collaboration and supply agreement on their CPI. In addition, the topline data from the ongoing Phase I/II trial in gastrointestinal stromal tumours (GIST) are expected to be announced in mid-2019. Immunicum completed a SEK351m (gross) combined stock issue in Q418.


**INDUSTRY OUTLOOK**

IO is a frenetic pharmaceutical development area with many clinical combination studies being conducted by big pharmaceutical companies. Investors may not need to wait until 2019 for price-moving events depending on the announcements on the start of their combination studies.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	0.0	(80.6)	(80.3)	(309.0)	N/A	N/A
2018e	0.0	(95.8)	(95.9)	(193.9)	N/A	N/A
2019e	0.0	(266.8)	(266.8)	(289.2)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK151.40  
 Market cap: SEK2622m  
 Market NASDAQ OMX First North

**Share price graph (SEK)**

**Company description**

Immunovia is a Swedish company, specialised in diagnostics for oncology and autoimmune diseases. Its main product is IMMray PanCan-d, an antibody microarray based on its proprietary IMMray platform. A prospective trial in high-risk patients will start in Q416. The company expects to generate initial out-of-pocket sales in 2018.

**Price performance**

%	1m	3m	12m
Actual	9.2	2.3	67.3
Relative*	1.4	(4.1)	60.3

\* % Relative to local index

**Analyst**

Dr John Savin

## Immunovia (IMMUNOV)

**INVESTMENT SUMMARY**

Immunovia announced Year-end cash of SEK 386m after operating expenses of SEK 114m; including SEK 25m of capitalised R&D. The IMMray PanCan-d test (for early detection of pancreatic cancer) is being optimised to deal with sample variability. An update will be issued in March 2019. Private tests could be sold from late 2019 to people at risk of familial pancreatic cancer. Tests will be run using in-house labs in the US and Sweden. This requires FDA CLIA approval and EU CE marking to be gained.

**INDUSTRY OUTLOOK**

Immunovia aims to gain reimbursement from the prospective PANFAM-1 study in familial pancreatic cancer. It is evaluating its test in older patients with diagnosed Type 2 diabetes, PANDIA-1. Additionally, IMMray has shown potential in immune diseases and lung cancer in preliminary studies. The company's goal is to reach SEK250-300m in turnover in 2022 from self pay and a turnover of SEK800-1,000m in 2024 after reimbursement. Longer-term, Type 2 diabetes and RA/lung cancer are massive opportunities.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2017	0.2	(44.3)	(45.2)	(267.0)	N/A	N/A
2018	1.1	(84.9)	(86.5)	(467.0)	N/A	N/A
2019e	0.7	(85.8)	(88.8)	(453.0)	N/A	N/A
2020e	N/A	N/A	N/A	N/A	N/A	N/A

**Sector: Pharma & healthcare**

Price: A\$0.03  
 Market cap: A\$102m  
 Market ASX

**Share price graph (A\$)**

**Company description**

Immutep has a pipeline of four LAG-3 related product candidates: eftilagimod alpha (IMP321) for cancer chemo-immunotherapy and immunotherapy-immunotherapy combinations, two partnered products IMP731 (GSK) and IMP701 (Novartis), as well as IMP761 for autoimmune diseases.

**Price performance**

%	1m	3m	12m
Actual	(3.2)	(18.9)	36.4
Relative*	(7.6)	(23.2)	33.3

\* % Relative to local index

**Analyst**

Dr Dennis Hulme

## Immutep (IMM)

**INVESTMENT SUMMARY**

Immutep has three promising candidates in clinical trials and one preclinical asset, all based on Lymphocyte activation gene-3, LAG-3 (one partnered with GSK and a second partnered with Novartis). Lead in-house LAG-3 product, eftilagimod alpha (efti), is being developed in metastatic breast cancer combined with chemo (179 of 226 patients recruited in randomised Phase IIb, topline PFS data expected H219) and in melanoma in combination with Keytruda (61% exploratory response rate from start of Keytruda monotherapy screening in three dose-finding cohorts, 3/6 (50%) responders in an additional cohort). Novartis and GSK are progressing clinical trials of partnered LAG-3 programmes: GSK has announced ulcerative colitis as lead indication; Novartis has commenced three Phase II studies with LAG525. Immutep is collaborating with Merck & Co (MSD) in a study of efti plus Keytruda in lung and head and neck cancers (first data H219). A trial of efti plus Bavencio in collaboration with Merck KGaA/Pfizer is planned for H119.


**INDUSTRY OUTLOOK**

Immunotherapies are among the most promising class of products for cancer and autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct mechanisms and applications.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	4.1	(7.8)	(8.4)	(0.4)	N/A	N/A
2018	6.9	(11.4)	(10.9)	(0.5)	N/A	N/A
2019e	10.9	(7.6)	(6.9)	(0.2)	N/A	N/A
2020e	2.8	(15.3)	(14.9)	(0.5)	N/A	N/A

**Sector: Pharma & healthcare**

Price: C\$0.61  
 Market cap: C\$104m  
 Market: TSX

**Share price graph (C\$)**

**Company description**

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its platform may be able to produce cannabinoids for less cost and with improved purity compared to currently used methods. The company is developing a pipeline, including INM-750 for epidermolysis bullosa, a serious, debilitating orphan indication.

**Price performance**

%	1m	3m	12m
Actual	29.8	10.9	(46.0)
Relative*	23.3	6.1	(47.5)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## InMed Pharmaceuticals (IN)

**INVESTMENT SUMMARY**

InMed is a Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Through its biosynthesis platform, the company believes it has distinct advantages over both naturally sourced and chemically synthesized cannabinoids, which could give it access to both the medical and retail markets, although the process is still in development. The company is also developing a proprietary pipeline, including INM-750 for epidermolysis bullosa (EB), a serious orphan indication, and expects to file a CTA for INM-750 in H219 with initiation of a 30 person Phase I by the end of the year.

**INDUSTRY OUTLOOK**

The market for cannabinoids, whether FDA-approved, medical or recreational is growing at a fantastic rate. Legal cannabis sales in the US alone were around \$7.5 billion in 2017 and we expect it to grow to \$28 billion by 2023.

Y/E Jun	Revenue (C\$m)	EBITDA (C\$m)	PBT (C\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	0.0	(3.3)	(3.2)	(3.27)	N/A	N/A
2018	0.0	(5.5)	(5.3)	(3.74)	N/A	N/A
2019e	0.0	(8.5)	(8.0)	(4.64)	N/A	N/A
2020e	0.0	(13.2)	(13.0)	(7.28)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$1.48  
 Market cap: US\$10m  
 Market: OTC

**Share price graph (US\$)**

**Company description**

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells (hpSCs). Its lead candidate is a cell therapy treatment for Parkinson's disease.

**Price performance**

%	1m	3m	12m
Actual	(3.3)	(9.8)	(6.3)
Relative*	(9.0)	(11.2)	(7.8)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## International Stem Cell (ISCO)

**INVESTMENT SUMMARY**

International Stem Cell (ISCO) is an early-stage cell therapy company in Phase I/IIa clinical trials to treat Parkinson's disease (PD), and recently completed dosing of the second patient in their third cohort (a total of 10 so far). Updated data were recently released and indicated that off-time percentage decreased an average of 49% for the second cohort at six months post-transplantation. Also, with its hpSC technology, ISCO has created 15 stem cell lines, each of which is a different HLA type. From this, it creates different cell types such as liver cells, neural cells and three-dimensional eye structures. Sales of its biomedical business were up 112.8% in Q318 to \$2.8m.

**INDUSTRY OUTLOOK**

ISCO's technology platform is based on human parthenogenetic stem cells (hpSCs). Parthenogenetic stem cells are created from unfertilized human eggs (oocytes) chemically activated to make the cells pluripotent. As hpSCs express fewer parental histocompatibility antigens, they reduce the risk of immune rejection.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	7.2	(4.5)	(4.9)	(152.07)	N/A	N/A
2017	7.5	(4.6)	(4.9)	(118.86)	N/A	N/A
2018e	11.5	(2.8)	(3.2)	(50.00)	N/A	N/A
2019e	13.5	(5.9)	(7.0)	(104.69)	N/A	N/A

**Sector: Pharma & healthcare**

Price: A\$0.46  
 Market cap: A\$28m  
 Market: ASX

**Share price graph (A\$)**



**Company description**

Kazia Therapeutics has two clinical stage anti-cancer drugs: GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer). GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.

**Price performance**

%	1m	3m	12m
Actual	23.0	18.2	(13.3)
Relative*	17.4	12.0	(15.3)

\* % Relative to local index

**Analyst**

Dr Dennis Hulme

## Kazia Therapeutics (KZA)

**INVESTMENT SUMMARY**

Kazia Therapeutics is developing two groups of anti-cancer compounds, including GDC-0084, a PI3K inhibitor licensed from Genentech that has been granted orphan designation in the US for glioblastoma. It began recruitment in a US-based Phase II programme for GDC-0084 in Q118; an initial Phase IIa dose-optimisation study will precede a randomised Phase IIb trial in 224 first-line glioblastoma patients (final data due 2021). It will also investigate GDC-0084 in breast cancer brain metastases (in collaboration with Dana Farber) and in the childhood brain cancer DIPG (with St Jude Hospital). The Phase I trial of its third-generation benzopyran drug Cantrixil in ovarian cancer has identified the MTD and is recruiting a 12-patient expansion cohort to further explore safety and potential efficacy. While the primary aim of the dose escalation phase was to assess safety and tolerability, we note that 3/5 patients achieved stable disease after two cycles, one of whom went on to achieve a partial response when treated with Cantrixil in combination with chemo.

**INDUSTRY OUTLOOK**

Kazia Therapeutics is a biotechnology company listed on the ASX and NASDAQ. Its two main drug technology platforms are third-generation benzopyrans and a PI3K inhibitor.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	8.6	(10.2)	(10.9)	(22.81)	N/A	N/A
2018	13.0	(4.9)	(6.3)	(12.48)	N/A	N/A
2019e	3.1	(10.5)	(11.9)	(21.92)	N/A	N/A
2020e	12.3	(1.9)	(3.2)	(5.32)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €5.56  
 Market cap: €147m  
 Market: Scale

**Share price graph (€)**



**Company description**

MagForce has a European approved nanotechnology-based therapy to treat brain cancer. Nanoparticles are injected into the tumour and activated by an external magnetic field, producing heat and thermally destroying or sensitising the tumour.

**Price performance**

%	1m	3m	12m
Actual	1.3	(6.4)	(27.0)
Relative*	(2.4)	(6.0)	(20.3)

\* % Relative to local index

**Analyst**

Dr Susie Jana

## MagForce (MF6)

**INVESTMENT SUMMARY**

MagForce is progressing its strategy to drive uptake and acceptance (in the US and Europe) of its NanoTherm nanoparticle-based therapy for cancer. MagForce has three centres in Germany that are commercially capable of treating glioblastoma patients. To accelerate uptake in Europe, MagForce is expanding from Germany into other countries with a loan of up to €35m from the European Investment Bank. Installation of the first device in Lublin, Poland has been achieved, with further expansion anticipated in 2019. In the US, its subsidiary MagForce USA has initiated a pivotal clinical trial for prostate cancer. Proceeds from the MagForce USA capital increase (\$9m gross) in August will finance the trial to completion, with commercial treatments potentially starting in Q419 (following regulatory approval).

**INDUSTRY OUTLOOK**


MagForce's NanoTherm therapy has been designed to directly affect tumours from within, while sparing surrounding healthy tissue. Magnetic nanoparticles are directly injected into a tumour and are then heated in the presence of an external magnetic field generated by specialist equipment (NanoActivator). This can destroy or sensitise the tumour for additional treatment.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.5	(6.6)	(7.2)	(27.8)	N/A	N/A
2017	0.7	(6.7)	(7.5)	(28.3)	N/A	N/A
2018e	0.3	(10.2)	(11.4)	(43.2)	N/A	N/A
2019e	5.8	(7.8)	(9.1)	(34.4)	N/A	N/A



**Sector: Pharma & healthcare**

Price: €8.49  
 Market cap: €208m  
 Market: FRA

**Share price graph (€)**

**Company description**

Medigene is a German biotech company with a core business in cancer immunotherapy. A T cell receptor (TCR) candidate has recently entered the clinic and a dendritic cell (DC) vaccine Phase I/II clinical study is ongoing in Phase II.

**Price performance**

%	1m	3m	12m
Actual	(5.2)	(10.6)	(49.3)
Relative*	(8.7)	(10.2)	(44.6)

\* % Relative to local index

**Analyst**

Dr Daniel Wilkinson

## Medigene (MDG1)

**INVESTMENT SUMMARY**

Medigene is focused on the rapid development of its cancer immunotherapy technology platforms: dendritic cell (DC) cancer vaccines, adoptive T-cell therapy (TCR) and T-cell specific antibodies (TAB). A Phase II study is ongoing with DC vaccines for acute myeloid leukaemia. For TCRs, Medigene has initiated its first company-led trial with MDG1011 in patients with PRAME expressing AML, MDS or MM. Medigene has announced an exclusive licence agreement with Leiden University to develop TCRs against HA-1 antigen. Its partnership with bluebird bio to utilise its TCR technology platform was recently expanded (US\$8m one time payment, US\$1m achieved milestone payment, US\$250 milestones per target, tiered royalties) to now include six therapeutic candidates. Medigene is well-funded to execute its clinical programme, as of 30 September net cash (including time deposits) was €76.3m.

**INDUSTRY OUTLOOK**

Cancer immunotherapy is attracting huge biotech investor interest. Medigene's DC vaccine technology is a new generation, with multiple potential efficacy and manufacturing benefits over the forerunners, eg Provenge. The TCR programme has similarities to CAR-T products, but with potentially significant efficacy and safety advantages.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	9.7	(12.4)	(13.4)	(66.20)	N/A	N/A
2017	11.4	(12.1)	(12.4)	(60.42)	N/A	N/A
2018e	10.4	(16.7)	(16.3)	(70.03)	N/A	N/A
2019e	11.0	(17.9)	(17.1)	(70.01)	N/A	N/A

**Sector: Pharma & healthcare**

Price: A\$1.17  
 Market cap: A\$581m  
 Market: ASX

**Share price graph (A\$)**

**Company description**

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

**Price performance**

%	1m	3m	12m
Actual	(11.7)	(18.0)	(9.0)
Relative*	(15.7)	(22.3)	(11.1)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Mesoblast (MSB)

**INVESTMENT SUMMARY**

The potentially pivotal 55 paediatric patient acute graft vs host disease (GvHD) study met its primary endpoint, with a 69% overall response rate vs 45% for historical controls (p=0.0003). Survival at day 180 was 69% compared to historical rates of 10–30% in Grade C/D disease patients. Based on these results, the company is working towards a pre-BLA meeting in the next few months. Importantly, the Phase IIb data in 159 end-stage CHF patients with an LVAD was presented at a late-breaking session at the American Heart Association (AHA). While the trial missed the primary endpoint, the company highlighted there was a significant reduction in major GI bleeding events (p=0.02), which based on prior feedback from the FDA is a clinically meaningful outcome.

**INDUSTRY OUTLOOK**

Mesoblast is a leading mesenchymal stem cell company. It has a manufacturing alliance with Lonza. JCR Pharmaceuticals markets Mesoblast's GvHD therapy in Japan; FY18 royalties were US\$3.6m plus a US\$1.5m milestone.

Y/E Jun	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2017	1.9	(82.2)	(83.3)	(17.69)	N/A	N/A
2018	17.0	(66.2)	(68.6)	(8.35)	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A
2020e	N/A	N/A	N/A	N/A	N/A	N/A



**Sector: Pharma & healthcare**

Price: A\$0.04  
 Market cap: A\$49m  
 Market: ASX

**Share price graph (A\$)**

**Company description**

MGC Pharmaceuticals (ASX: MXC) is an Australia-headquartered specialist medical cannabis biopharma company, which has most of its operations based in Europe. Management has many years of technical, clinical and commercial experience in the medical cannabis industry.

**Price performance**

%	1m	3m	12m
Actual	(7.0)	2.6	(63.6)
Relative*	(11.2)	(2.8)	(64.5)

\* % Relative to local index

**Analyst**

Dr Dennis Hulme

## MGC Pharmaceuticals (MXC)

**INVESTMENT SUMMARY**

MGC Pharmaceuticals is developing cannabis-based pharmaceutical products, initially in Australia and Europe. It is already growing medicinal cannabis crops in the Czech Republic and has established in Slovenia one of the few fully GMP-certified resin extraction and separation plants in Europe. It plans to establish larger-scale operations in Malta under a contract awarded by the Maltese government in April 2018. In December it imported the first shipment of GMP-certified CannEpil into Australia, where it can be prescribed as an investigational medicinal product under an authorisation received from the Therapeutic Goods Administration. The company intends to develop CannEpil and CogniCann as registered pharmaceutical treatments for refractory epilepsy, and to improve quality of life in dementia patients, respectively. In January MGC completed the sale of its MGC Derma cannabis-based cosmetics business to Cannaglobal in exchange for a 10% equity interest in CannaGlobal and a five-year exclusive supply agreement.

**INDUSTRY OUTLOOK**

Increasing acceptance and regulatory approvals in many countries have made medicinal cannabis a fast-growing industry. Cannabinoids have generated promising data in many indications and are attracting considerable interest.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	0.1	(8.5)	(8.5)	(0.88)	N/A	N/A
2018	0.3	(8.9)	(9.0)	(0.80)	N/A	N/A
2019e	2.3	(5.7)	(5.7)	(0.45)	N/A	N/A
2020e	8.9	(6.4)	(6.6)	(0.50)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €2.35  
 Market cap: €22m  
 Market: FRA

**Share price graph (€)**

**Company description**

Mologen is a German biotech company developing cancer immunotherapies. The lead product is lefitolimod (MGN1703) for metastatic colorectal cancer maintenance, SCLC and HIV. Development of MGN1601, a therapeutic renal cell vaccine, would be reinitiated on successful out-licensing of lefitolimod.

**Price performance**

%	1m	3m	12m
Actual	2.8	(38.2)	(79.4)
Relative*	(0.9)	(37.9)	(77.5)

\* % Relative to local index

**Analyst**

Dr Susie Jana

## Mologen (MGN)

**INVESTMENT SUMMARY**

Mologen is developing novel immunotherapies for use in the post-chemo maintenance setting (in cancer) and for the treatment of infectious diseases. A pivotal 540-pt Phase III study (IMPALA) for its lead asset lefitolimod in metastatic colorectal cancer maintenance will read out in H219. Mologen recently terminated negotiations with Oncologie for the global assignment of lefitolimod following deal terms that were inferior to those originally agreed. Mologen will now look to out-license lefitolimod after the IMPALA trial to achieve the best possible terms. An agreement with the principle bond holder for its 2016/2024 and 2017/2025 bonds has averted the immediate repayment of both bonds (totalling €6.6m); this is still subject to the approval of creditors, which has been postponed until after the EGM on 26 February 2019. We place our valuation under review.


**INDUSTRY OUTLOOK**

Immunotherapies are among the most promising class of products for cancer. Mologen's lead asset lefitolimod is an immunotherapy in development for both cancer maintenance and combination therapies.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.1	(20.6)	(20.8)	(4.22)	N/A	N/A
2017	0.0	(18.7)	(19.3)	(2.81)	N/A	N/A
2018e	3.0	(13.6)	(14.2)	(1.53)	N/A	N/A
2019e	0.0	(16.3)	(17.0)	(1.84)	N/A	N/A

**Sector: Pcare & household prd**

Price: 2.2p  
Market cap: £2m  
Market: AIM

**Share price graph (p)**

**Company description**

NetScientific is a transatlantic biomedical and healthcare technology group. Its portfolio of five core investments and one material investment is focused on three main sectors: digital health (Wanda), diagnostics (Vortex, ProAxis, Glycotest) and therapeutics (PDS Biotech).

**Price performance**

%	1m	3m	12m
Actual	(30.6)	(91.8)	(96.3)
Relative*	(33.7)	(92.0)	(96.2)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## NetScientific (NSCI)

**INVESTMENT SUMMARY**

NetScientific has a focused portfolio of potentially disruptive biomedical and healthcare technology investments. The company is focused on digital health, diagnostics and therapeutics with the portfolio consisting of four core investments in which it has controlling stakes (Vortex, Wanda, ProAxis and Glycotest) and one material investment (PDS). Importantly, Glycotest announced that Fosun Pharma agreed to a \$10m investment in Glycotest in exchange for a 40% interest in the company as well as the China rights for Glycotest's hepatocellular carcinoma panel. PDS also recently agreed to merge with Nasdaq-listed Edge Therapeutics. NetScientific has initiated an exploration of strategic alternatives.

**INDUSTRY OUTLOOK**

NetScientific remains focused on sourcing, funding and building early- to mid-stage US and UK companies that are developing potentially breakthrough technologies in growing markets with unmet needs.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	0.5	(12.6)	(12.3)	(20.6)	N/A	N/A
2017	0.4	(10.8)	(9.5)	(13.6)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK1.44  
Market cap: SEK264m  
Market: NASDAQ OTCQX

**Share price graph (SEK)**

**Company description**

NeuroVive Pharmaceutical is a Swedish biopharmaceutical company with deep expertise in mitochondrial medicine. It has a diversified portfolio in terms of indications and employs a dual strategy: it develops a core portfolio of assets for orphan diseases and seeks to out-license proprietary products for non-orphan indications.

**Price performance**

%	1m	3m	12m
Actual	(6.4)	(52.3)	(30.5)
Relative*	(13.1)	(55.3)	(33.4)

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## NeuroVive Pharmaceutical (NVP)

**INVESTMENT SUMMARY**

NeuroVive Pharmaceutical is a mitochondrial medicine specialist. NeuroVive's core portfolio targets orphan indications: traumatic brain injury (TBI) with NeuroSTAT, various genetic mitochondrial diseases with KL1333 and NVP015, and mitochondrial myopathy with NVP025. NeuroVive has received positive feedback from the FDA on its NeuroSTAT TBI development plan including the design of the Phase IIb proof-of-concept study. The study is expected to start in 2019. The second most advanced product KL1333, in-licensed from Yungjin Pharm in May 2017, demonstrated positive results in the Phase I trial in South Korea and NeuroVive is planning to start a Phase Ib study in H119. Recent highlights include the capital raise of SEK99m on 11 February 2019 and the out-licensing of a subset of compounds from the NVP015 programme for localised treatment of LHON to BridgeBio Pharma for a deal valued at around \$60m in 2018.

**INDUSTRY OUTLOOK**

NeuroVive has a diversified portfolio with all assets aimed at improving mitochondrial metabolism and function. This puts NeuroVive among the very few experts in mitochondrial medicine in the industry, in our view.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	0.0	(69.9)	(70.7)	(172.27)	N/A	N/A
2017	0.6	(67.9)	(70.1)	(149.31)	N/A	N/A
2018e	1.5	(69.3)	(69.7)	(102.28)	N/A	N/A
2019e	1.5	(132.8)	(133.0)	(106.64)	N/A	N/A

**Sector: Pharma & healthcare**

Price: CHF8.72  
 Market cap: CHF156m  
 Market Swiss Stock Exchange

**Share price graph (CHF)**

**Company description**

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Seqirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

**Price performance**

%	1m	3m	12m
Actual	21.3	17.0	(15.0)
Relative*	15.8	12.3	(18.0)

\* % Relative to local index

**Analyst**

Dr Susie Jana

## Newron Pharmaceuticals (NWRN)

**INVESTMENT SUMMARY**

Newron's lead product, Xadago (safinamide) for Parkinson's disease (PD) has been launched in 14 European countries through commercial partner Zambon and in the US by sublicensee US WorldMeds. Royalty income from sales of Xadago rose by 54% (to €2m) y-o-y in H118 and in November Xadago received marketing approval in Australia (through partners Zambon and Seqirus). The pivotal Phase II/III trial (STARS), investigating sarizotan for awake breathing disorders associated with Rett syndrome, is expected to report top-line data in Q319. Following positive data from a Phase II study of Evenamide, two Phase II/III studies are expected to initiate in Q219, to investigate Evenamide as an add-on to atypical antipsychotics in schizophrenia. As of 30 June, Newron had net cash and short-term investments of €50.6m.

**INDUSTRY OUTLOOK**

The market for treating CNS disorders is substantial and growing. Xadago has a unique position as an add-on to levodopa therapy in Parkinson's disease, with its once-a-day dosing and a clean safety profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	6.7	(15.3)	(15.2)	(103.69)	N/A	N/A
2017	13.4	(4.3)	(5.3)	(32.32)	N/A	N/A
2018e	5.6	(24.7)	(24.5)	(137.90)	N/A	N/A
2019e	10.7	(28.3)	(28.2)	(158.27)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK13.24  
 Market cap: SEK656m  
 Market NASDAQ OMX First North

**Share price graph (SEK)**

**Company description**

Nuevolution is a Copenhagen-based biopharmaceutical company. Its patent protected Chemetics drug discovery platform enables the selection of drugs to an array of tough-to-drug disease targets. To date it has entered into 17 agreements with major pharmaceutical companies.

**Price performance**

%	1m	3m	12m
Actual	(15.8)	(17.3)	(22.1)
Relative*	(21.8)	(22.4)	(25.4)

\* % Relative to local index

**Analyst**

Dr Daniel Wilkinson

## Nuevolution (NUEV)

**INVESTMENT SUMMARY**

Nuevolution's proprietary Chemetics DNA-encoded screening platform technology enables fast and accurate small molecule drug discovery. Nuevolution has continued to build and strengthen its pipeline of preclinical assets throughout 2018, which it aims to monetise in the near term via out-licensing deals. The technology has received powerful external validation, including three collaborations (Amgen, Almirall and Janssen) that could generate significant value in the coming years. We expect Nuevolution to see at least one internally generated asset progress into clinical development in the near future. As of 30 September, Nuevolution had net cash of SEK127m.

**INDUSTRY OUTLOOK**

Significant promise is seen in DNA-encoded libraries due to the potential to rapidly develop small molecule drugs to 'tough-to-drug' targets. We continue to see major investment in the space from an array of companies, notably GSK, Roche and Novartis.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	21.3	N/A	(151.9)	(4.0)	N/A	N/A
2017	120.3	N/A	(9.4)	(0.6)	N/A	N/A
2018e	11.5	N/A	(109.0)	(2.2)	N/A	N/A
2019e	196.4	N/A	75.3	1.0	1324.0	9.8

**Sector: Pharma & healthcare**

Price: SEK6.70  
 Market cap: SEK337m  
 Market: NASDAQ OMX First North

**Share price graph (SEK)**

**Company description**

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

**Price performance**

%	1m	3m	12m
Actual	(2.9)	(24.7)	(36.5)
Relative*	(9.8)	(29.4)	(39.2)

\* % Relative to local index

**Analyst**

Dr Nathaniel Calloway

## Oncology Venture (OV.ST)

**INVESTMENT SUMMARY**

Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. The company's goal is to then identify and in-license drugs that are active within populations that the DRP can identify. To date, the company has in-licensed six drugs and is in the early stages of validating the platform in the clinic.

**INDUSTRY OUTLOOK**

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Y/E Dec	Revenue (DKKm)	EBITDA (DKKm)	PBT (DKKm)	EPS (ore)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	5.1	(23.8)	(31.0)	(127.00)	N/A	N/A
2018e	3.2	(38.4)	(29.2)	(56.99)	N/A	N/A
2019e	1.9	(204.6)	(205.8)	(382.13)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €0.91  
 Market cap: €49m  
 Market: Euronext Paris

**Share price graph (€)**

**Company description**

Onxeo is developing innovative oncology drugs based on DNA-targeting and epigenetics. The lead compound, AsiDNA, is a first-in-class DNA break repair inhibitor based on a unique decoy mechanism and currently evaluated in a phase I trial (DRIIV-1) for systemic administration in solid tumors.

**Price performance**

%	1m	3m	12m
Actual	(7.7)	(6.8)	(44.0)
Relative*	(13.9)	(8.2)	(42.6)

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## Onxeo (ONXEO)

**INVESTMENT SUMMARY**

Onxeo's lead asset AsiDNA, a first-in-class DNA break repair inhibitor, is now being tested in the Phase Ib/II part of the DRIIV-1 trial at the Institut Curie in Paris in patients with advanced solid tumours. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection, but is now being tested via systemic administration. Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. AsiDNA is part of the proprietary, novel platON platform, a major R&D expansion announced in October 2017, and is based on decoy oligonucleotides. The platON platform belongs to the so-called DNA damage response (DDR) technology, a domain to which recently marketed PARP inhibitors also belong. After receiving \$7.5m from the sale of rights to royalties from Beleodaq and a €5.4m equity financing line, cash reach will extend into Q320 past the AsiDNA Phase I results.

**INDUSTRY OUTLOOK**

The approval of the first PARP inhibitor (olaparib) has kick started the interest of both the scientific community and large pharma in the DNA Damage Response (DDR) field. Few biotechs are already positioned in this emerging field which may be the successor to immuno-oncology.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	4.4	(21.3)	(20.4)	(44.64)	N/A	N/A
2017	9.5	(17.4)	(19.7)	(23.58)	N/A	N/A
2018e	3.4	(7.2)	(7.8)	(11.83)	N/A	N/A
2019e	3.5	(11.8)	(11.9)	(22.56)	N/A	N/A

**Sector: Pharma & healthcare**

Price: SEK72.50  
 Market cap: SEK2506m  
 Market NASDAQ OMX Mid Cap

**Share price graph (SEK)**



**Company description**

Orexo is a Swedish speciality pharma company, with expertise in drug delivery/reformulation technologies (in particular sublingual formulations) and a US commercial infrastructure for opioid dependence therapy Zubsolv (also filed in Europe). Orexo also has two clinical assets and three preclinical programmes.

**Price performance**

%	1m	3m	12m
Actual	8.4	22.3	103.4
Relative*	0.6	14.6	94.8

\* % Relative to local index

**Analyst**

Andy Smith

## Orexo (ORX)

**INVESTMENT SUMMARY**

Orexo generated positive EBITDA and operating cash flow generation in FY16, FY17 and FY18. US commercial and public formulary coverage is dynamic but exclusive contracts with Humana, among other insurers, are having a positive impact on US Zubsolv volumes and sales. The IP infringement appeal on the US Zubsolv IP was resolved in Orexo's favor without recourse. Zubsolv generics are precluded before September 2032 and other patent cases against Actavis are ongoing. Zubsolv was approved in Europe in 2018 and is being partnered in the EU. Orexo's focus now shifts to business development, M&A and sales force leverage while its CoGS reduction is expected to result in a material improvement in profitability. We are cautious on the effect of multiple generic Suboxone film entries on Zubsolv's US market share but point to many other sources of upside in 2019.

**INDUSTRY OUTLOOK**

Opioid dependence diagnosis/treatment rates are low due to social stigma, limited access to therapy in parts of the US and affordability. Competition includes Suboxone film (Indivior), Bunavail (BDSI) and six generic bup/nal tablets.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2017	643.7	57.4	29.7	67.00	108.2	16.3
2018	783.1	95.8	92.2	399.01	18.2	17.1
2019e	866.7	265.2	252.7	708.38	10.2	13.4
2020e	844.1	176.2	156.6	439.08	16.5	9.8

**Sector: Pharma & healthcare**

Price: €3.79  
 Market cap: €148m  
 Market Madrid Stock Exchange

**Share price graph (€)**



**Company description**

Oryzon Genomics is a Spanish biotech focused on epigenetics. Iadademstat (ORY-1001, Phase IIa) is being explored for acute leukaemias and SCLC; Vafidemstat (ORY-2001) is in Phase IIa for AD, MS and aggression, and ORY-3001 is being developed for certain orphan indications.

**Price performance**

%	1m	3m	12m
Actual	37.3	24.5	43.6
Relative*	33.2	23.8	52.9

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## Oryzon Genomics (ORY)

**INVESTMENT SUMMARY**

Oryzon's expertise lies in developing small molecule inhibitors for epigenetic targets. Oryzon's lead CNS product vafidemstat (ORY-2001), a dual LSD1/MAOB inhibitor, targets Alzheimer's disease (Phase IIa initiated), multiple sclerosis (Phase IIa initiated) and other neurodegenerative indications. Results from both trials are expected in 2019. Oryzon has also initiated a Phase IIa trial studying vafidemstat (ORY-2001) in aggressiveness. The lead oncology product iadademstat (ORY-1001) is a specific LSD1 inhibitor with positive data from the Phase I/IIa in acute myeloid leukaemia (AML) announced in December 2016. A Phase IIa trial in AML and Phase IIa trial in SCLC have recently initiated.

**INDUSTRY OUTLOOK**

Epigenetics is a relatively young field in terms of drug development. HDACs were among the first epigenetic therapeutics brought to market, and although effective, they have side effects. Oryzon is among the leading clinical stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and are expected to show a favourable safety/efficacy profile.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	5.0	(3.7)	(4.7)	(17.02)	N/A	N/A
2017	4.3	(3.5)	(4.6)	(14.29)	N/A	N/A
2018e	7.0	(4.7)	(5.6)	(9.23)	N/A	N/A
2019e	6.3	(6.4)	(7.3)	(18.56)	N/A	N/A



**Sector: Pharma & healthcare**

Price: €4.12  
 Market cap: €61m  
 Market: Euronext Paris

**Share price graph (€)**

**Company description**

OSE Immunotherapeutics is an immunotherapy company based in Nantes and Paris, France and listed on the Euronext Paris exchange. OSE is currently developing immunotherapies for the treatment of solid tumours and autoimmune diseases and has established several partnerships with large pharma companies.

**Price performance**

%	1m	3m	12m
Actual	22.3	27.6	12.9
Relative*	14.0	25.6	15.7

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## OSE Immunotherapeutics (OSE)

**INVESTMENT SUMMARY**

OSE Immunotherapeutics is a drug developer that focuses on both oncology and immune disorders, with an R&D pipeline diversified across different indications and mechanisms of action. Long-term collaborations with top research institutions enable the company to identify novel targets in a cost-effective and time-efficient manner, and develop products for R&D and out-licensing. The success of this model is demonstrated by several commercial partnerships, including a deal with Boehringer Ingelheim (BI) in April 2018 for a total value of €1.1bn plus royalties. OSE's most advanced internal programme is Tedopi for NSCLC (Phase III), with results expected in 2021. In February 2019, a milestone payment was triggered from Servier of €10m.

**INDUSTRY OUTLOOK**

OSE operates within the field of immunotherapy, and has products in development for both immunological diseases and cancer indications. We expect OSE's strong relationships with research institutions and internal expertise to be a significant advantage in continuing to develop pipeline products with partnering potential.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2016	0.4	(6.8)	(6.9)	(30.32)	N/A	75.5
2017	6.7	(12.5)	(12.6)	(72.33)	N/A	N/A
2018e	20.6	0.4	0.8	5.59	73.7	N/A
2019e	0.0	(19.9)	(20.0)	(136.09)	N/A	N/A

**Sector: Pharma & healthcare**

Price: 697.6p  
 Market cap: £461m  
 Market: LSE

**Share price graph (p)**

**Company description**

Oxford BioMedica's (OXB) LentiVector technology underpins the company's strategy. OXB generates significant revenue from partners that utilise its technology, notably Novartis, Bioverativ, Orchard Therapeutics and Immune Design. OXB is in partnering discussions about internally developed assets.

**Price performance**

%	1m	3m	12m
Actual	11.8	7.0	16.3
Relative*	6.9	4.4	17.0

\* % Relative to local index

**Analyst**

Dr Daniel Wilkinson

## Oxford BioMedica (OXB)

**INVESTMENT SUMMARY**

Oxford BioMedica (OXB) is a global leader in lentiviral development and manufacturing. Maiden interim profits reported this year are evidence of strong operational momentum and ongoing validation of its business model. On the back of a £19.3m net raise in March, OXB is expanding its manufacturing capabilities to match increasing demand and continued growth of its platform (partnership) revenues. In the near term, revenue will continue to be driven by the Novartis partnership as Kymriah's commercial roll out continues (royalties and manufacturing fees). OXB has several established development and manufacturing partnerships with Bioverativ, Sanofi & Orchard Therapeutics and continues to look to spin-out/out-license its internally developed, preclinical assets. Recently, partner Axovant announced that the development of AXO-Lenti-PD (in-licensed from OXB) was proceeding according to plan, with the first data from the ongoing SUNRISE-PD Phase II trial expected in Q119. As of 30 June, OXB had gross cash of £44.0m.

**INDUSTRY OUTLOOK**

Cell- and gene-therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. The proprietary lentivector platform has demonstrated promise in many indications.

Y/E Dec	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2016	27.8	(7.6)	(20.0)	(29.35)	N/A	N/A
2017	37.6	(1.3)	(11.5)	(14.14)	N/A	N/A
2018e	74.3	15.5	3.8	4.80	145.3	26.1
2019e	85.1	18.3	4.6	5.65	123.5	28.8



**Sector: Pharma & healthcare**

Price: NZ\$0.31  
 Market cap: NZ\$158m  
 Market: NZSX

**Share price graph (NZ\$)**

**Company description**

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

**Price performance**

%	1m	3m	12m
Actual	(8.8)	(22.5)	(22.5)
Relative*	(11.6)	(25.7)	(30.0)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Pacific Edge (PEB)

**INVESTMENT SUMMARY**

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests using its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia. The company recently announced results for H119, including 42.7% growth in Cxbladder sales compared to H118. Importantly, in October, the company received notification of the Cxbladder test national reimbursement rate (US\$760) from CMS. Once the company receives Local Coverage Determination (LCD), Pacific Edge will be able to get reimbursement for Medicare claims and will enable reimbursement and negotiation for payment on 14,000 tests previously performed on CMS patients. The LCD process is ongoing and once completed will be a major driver of future growth.

**INDUSTRY OUTLOOK**

Molecular diagnostics is a growing, but increasingly competitive field. Lead time from the initiation of user programmes to payment can be long.

Y/E Mar	Revenue (NZ\$m)	EBITDA (NZ\$m)	PBT (NZ\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	4.4	(22.3)	(22.4)	(5.9)	N/A	N/A
2018	4.6	(19.5)	(19.6)	(4.5)	N/A	N/A
2019e	5.0	(17.6)	(17.5)	(3.5)	N/A	N/A
2020e	10.2	(13.2)	(13.2)	(2.6)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €2.22  
 Market cap: €142m  
 Market: FRA

**Share price graph (€)**

**Company description**

PAION is a specialty pharma company developing anaesthesia products. Its lead product, remimazolam, is partnered with Mundipharma in Japan, Yichang in China, Hana Pharma in S Korea, Cosmo in the US, Pendopharm in Canada and R-Pharm in CIS, Turkey and MENA.

**Price performance**

%	1m	3m	12m
Actual	(4.3)	2.3	(7.5)
Relative*	(7.8)	2.8	1.1

\* % Relative to local index

**Analyst**

Dr Dennis Hulme

## Paion (PA8)

**INVESTMENT SUMMARY**

Paion is moving closer to commercialisation of remimazolam, its ultra-short-acting IV sedative/anaesthetic that combines the best features of approved agents midazolam and propofol. Partner Yichang Humanwell filed for approval of remimazolam in procedural sedation in China in November, and Mundipharma filed for approval in general anaesthesia (GA) in Japan in December. Cosmo is on track to file for US approval in Q119, after Paion successfully completed clinical development in procedural sedation. R-Pharm plans to file for approval in GA in Russia in Q119. The primary target in the US is to replace midazolam as the sedative of choice for procedures such as colonoscopy and bronchoscopy; faster induction and recovery with remimazolam reduces total procedure time and should increase throughput. Paion has initiated a Phase III in GA in Europe, with completion of recruitment expected in 2019. Cash of €19.8m at 30 September and anticipated milestone revenue is sufficient to report top-line data from the European Phase III.

**INDUSTRY OUTLOOK**

Remimazolam has important advantages over competing products, including fast onset and offset of action with lower risk of cardiopulmonary events than the standard-of-care midazolam and propofol, and a reversal agent exists if there is over sedation.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	4.3	(25.1)	(25.1)	(37.8)	N/A	N/A
2017	5.8	(15.9)	(15.9)	(20.5)	N/A	N/A
2018e	3.1	(13.7)	(13.6)	(17.9)	N/A	N/A
2019e	10.5	(9.4)	(9.4)	(10.2)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$3.33  
 Market cap: US\$486m  
 Market: NASDAQ

**Share price graph (US\$)**

**Company description**

PDL has reinvented itself through a three-pronged strategy: investing in royalty streams of marketed and development-stage therapeutics and providing high-yield debt financing to device & diagnostic companies with near-term product launches.

**Price performance**

%	1m	3m	12m
Actual	5.4	14.4	34.3
Relative*	(0.9)	12.6	32.1

\* % Relative to local index

**Analyst**

Maxim Jacobs

## PDL BioPharma (PDLI)

**INVESTMENT SUMMARY**

PDL BioPharma is a healthcare-focused company with a three-pronged strategy: investing in royalty streams, providing high-yield financing to life science companies with near-term product launches as well as purchasing approved drugs to be sold by Noden Pharma. This strategy allows investors to gain exposure in healthcare through a relatively low-risk, diversified vehicle. PDL reported Q318 revenues of \$67.9m, up 8.2% compared to Q317 and up 45.8% sequentially, with that growth mainly due to an increase in the fair value of the Assertio (formerly Depomed) royalty rights. Lee's Pharmaceutical Holdings, Noden's partner in China, is expected to launch Tekturma/Rasilez in H119. The company recently announced a \$100m stock repurchase plan which could buy back over a quarter of shares outstanding.

**INDUSTRY OUTLOOK**

PDL BioPharma is one of the only companies that will give broad exposure to diverse royalty streams as well as corporate debt and high margin approved products.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	244.3	193.1	175.5	77.72	4.3	5.4
2017	320.1	218.8	200.3	81.33	4.1	12.7
2018e	189.4	71.8	66.1	46.11	7.2	N/A
2019e	126.9	31.9	34.9	20.65	16.1	N/A

**Sector: Pharma & healthcare**

Price: NOK45.95  
 Market cap: NOK1001m  
 Market: Oslo

**Share price graph (NOK)**

**Company description**

Photocure specialises in photodynamic therapy. Its bladder cancer imaging product is sold as Hexvix in Europe and Cysview in the US. Photocure handles the marketing in Nordic countries and the US, while Ipsen is its marketing partner in the EU.

**Price performance**

%	1m	3m	12m
Actual	1.0	20.0	63.5
Relative*	(1.7)	20.1	55.9

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Photocure (PHO)

**INVESTMENT SUMMARY**

Photocure is a commercial-stage Norwegian specialty pharmaceutical company that currently markets Hexvix/Cysview for diagnosing and managing bladder cancer. Recently, the US Centers for Medicare & Medicaid Services (CMS) issued a final rule that would improve reimbursement for a large number of procedures. Also, following positive Phase III results in the surveillance setting, the company received FDA approval for that indication and launched the product in May. Sales may have significant upside if the product successfully expands into the US bladder cancer surveillance market, which has 1.2m-1.4m procedures per year, compared to its current market of 325,000 transurethral resection of the bladder (TURB) procedures.

**INDUSTRY OUTLOOK**

Photocure is a photodynamic therapy company focused on bladder cancer. As its products typically are a combination of a drug and a device, hurdles for generics are typically higher than with other therapeutics.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (öre)	P/E (x)	P/CF (x)
2016	143.6	(8.0)	12.8	164.0	28.0	51.5
2017	150.9	(33.1)	(41.6)	(161.0)	N/A	N/A
2018e	184.6	(8.8)	(21.9)	(73.0)	N/A	N/A
2019e	251.0	48.8	35.7	120.0	38.3	40.2

**Sector: Pharma & healthcare**

Price: €1.67  
 Market cap: €35m  
 Market: Euronext Paris

**Share price graph (€)**

**Company description**

Pixium Vision develops retinal implants for patients with severe vision loss. PRIMA, a wireless sub-retinal implant, designed for Dry-ARMD patients, is in a human clinical stage in Europe and is recruiting patients in its US feasibility study.

**Price performance**

%	1m	3m	12m
Actual	(3.0)	(17.5)	(42.3)
Relative*	(9.6)	(18.8)	(40.9)

\* % Relative to local index

**Analyst**

Pooya Hemami

## Pixium Vision (PIX)

**INVESTMENT SUMMARY**

Pixium Vision is developing the Prima wireless photovoltaic sub-retinal implant, which transforms images into electrical signals to elicit a form of central visual perception in patients with severe retinal disease. It announced in early 2019 positive data from its European feasibility study, designed to assess Prima in patients with advanced atrophic dry age-related macular degeneration. All five implantations were followed by successful activations (resulting in reported light perception in areas where there had been none prior to implantation). Pixium plans to start implantations as part of a five-patient US Prima feasibility study in early 2019 and to start an EU pivotal study in H219.


**INDUSTRY OUTLOOK**

Pixium held €15.6m in gross cash at 31 December 2018, which we estimate will fund operations into Q220. Prima has been designed and being evaluated in clinical studies as a potential treatment option for dry ARMD, a common disease in aging population and a significant unmet medical need.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2017	2.5	(11.7)	(13.5)	(102.07)	N/A	N/A
2018	1.6	(6.1)	(8.1)	(43.67)	N/A	N/A
2019e	1.6	(8.7)	(10.6)	(48.11)	N/A	N/A
2020e	0.0	(16.9)	(21.7)	(98.70)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €4.84  
 Market cap: €76m  
 Market: Euronext Paris

**Share price graph (€)**

**Company description**

Quantum Genomics is a biopharmaceutical company developing QGC001, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment.

**Price performance**

%	1m	3m	12m
Actual	1.8	17.7	83.5
Relative*	(5.1)	15.9	88.0

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Quantum Genomics (ALQGC)

**INVESTMENT SUMMARY**

Quantum Genomics is investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. The company recently released data from the Phase IIb NEW-HOPE trial, which strongly suggests that firibistat is an efficacious, safe drug. After eight weeks of treatment, patients saw a statistically significant reduction from baseline ( $p < 0.0001$ ) in systolic blood pressure of 9.7mmHg. A pivotal Phase III in resistant hypertension patients is expected to begin in H219. The company is also launching a Phase IIb in heart failure in Q219 with results expected in H220.

**INDUSTRY OUTLOOK**

The angiotensin pathway is one of the primary methods of modulating blood pressure and is the target of many anti-hypertensive drugs, including ACE's and ARB's. However, there is a parallel pathway in the brain responsible for the secretion of vasopressin and heart rate that is unaddressed by current drugs and that is being targeted by Quantum Genomics.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(6.2)	(6.2)	(59.79)	N/A	N/A
2017	0.0	(10.3)	(10.3)	(92.81)	N/A	N/A
2018e	0.0	(12.6)	(13.1)	(85.58)	N/A	N/A
2019e	0.0	(14.8)	(16.2)	(100.00)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$8.42  
 Market cap: US\$236m  
 Market: NASDAQ, TASE

**Share price graph (US\$)**

**Company description**

RedHill Biopharma is a specialty pharma company with a broad R&D pipeline focusing on gastrointestinal and inflammatory diseases and also promotes four GI products in the US. The most advanced programs are TALICIA (RHB-105) for H. pylori infection, RHB-104 for Crohn's disease, BEKINDA for gastroenteritis and IBS-D, and RHB-204 for NTM.

**Price performance**

%	1m	3m	12m
Actual	19.8	4.1	42.0
Relative*	12.6	2.4	39.7

\* % Relative to local index

**Analyst**

Dr Jonas Pecilius

## RedHill Biopharma (RDHL)

**INVESTMENT SUMMARY**

RedHill has a broad R&D pipeline, but is focusing on GI and inflammatory diseases. The most advanced assets are TALICIA (RHB-105) for H. pylori infection (NDA filing planned for H119); RHB-104 for Crohn's disease (positive top-line results from first Phase III announced July 2018); BEKINDA for both gastroenteritis (positive results from first Phase III announced June 2017) and IBS-D (positive final Phase II results announced January 2018); and RHB-204 for pulmonary non-tuberculous mycobacteria infections (pivotal Phase III trial to start mid-2019). RedHill promotes four GI products in the US (Donnatal, EnteraGam, Esomeprazole Strontium DR Capsules 49.3mg and Mytesi). RedHill raised \$20m gross from its recent offering in December 2018.

**INDUSTRY OUTLOOK**

RedHill's main focus on GI and inflammation include a range of conditions, which although can be treated with a variety of innovative and established products, there is still an unmet need in each of the diseases. In our view, carefully positioned, innovative solutions for the patients will attract attention.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.1	(30.5)	(29.4)	(22.85)	N/A	N/A
2017	4.0	(51.9)	(45.5)	(25.99)	N/A	N/A
2018e	9.5	(39.9)	(40.0)	(16.14)	N/A	N/A
2019e	12.4	(41.6)	(41.7)	(14.71)	N/A	N/A

**Sector: Pharma & healthcare**

Price: A\$0.13  
 Market cap: A\$27m  
 Market: ASX

**Share price graph (A\$)**

**Company description**

Regeneus is a clinical-stage regenerative medicine company developing innovative cell-based therapies for the human & animal health markets.

**Price performance**

%	1m	3m	12m
Actual	(18.8)	(38.1)	0.0
Relative*	(22.4)	(41.4)	(2.3)

\* % Relative to local index

**Analyst**

Dr Dennis Hulme

## Regeneus (RGS)

**INVESTMENT SUMMARY**

Regeneus is developing its mesenchymal stem cell technology for musculoskeletal conditions in humans (Progenza) and animals (CryoShot). It has entered a collaboration with AGC for exclusive manufacture of Progenza cells for Japan. Regeneus and AGC have formed a 50:50 JV, seeking to sub-license partners to develop and commercialise Progenza in Japan in several indications; the first Progenza clinical development licence deal is expected shortly. In Phase I, Progenza-treated patients experienced clinically meaningful reduction in knee pain and a significant improvement in lateral tibial knee cartilage. Regeneus was granted a US patent in July covering the composition and use of Progenza and it will soon be granted in Europe. Its autologous cancer vaccine RGS4K was safe and showed encouraging signs of immune stimulation and antitumour activity in a Phase I study. Its Sygenus topical secretions technology improved the appearance of acne in adults in a clinical study and produced better pain relief than morphine in preclinical studies.

**INDUSTRY OUTLOOK**

Regeneus focuses on early-stage product development, then partners. In addition to the AGC deal for Progenza in Japan, it has partnered with a global animal health company for CryoShot Canine. It will seek to identify wider applications of Progenza, beyond arthritis.

Y/E Jun	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2017	10.0	4.9	3.3	1.57	8.3	7.6
2018	0.6	(4.8)	(5.2)	(2.48)	N/A	N/A
2019e	7.8	2.3	2.2	1.04	12.5	11.8
2020e	1.6	(4.0)	(4.2)	(2.00)	N/A	N/A

**Sector: Pharma & healthcare**

Price: 51.5p  
 Market cap: £16m  
 Market: LSE

**Share price graph (p)**

**Company description**

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIb) and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

**Price performance**

%	1m	3m	12m
Actual	3.0	(14.9)	(50.2)
Relative*	(1.5)	(17.0)	(49.9)

\* % Relative to local index

**Analyst**

Andy Smith

## ReNeuron Group (RENE)

**INVESTMENT SUMMARY**

ReNeuron is focused on three cell therapy-based programs. The CTX neural stem cell program has demonstrated positive response rates in key measures were sustained after extended follow-up. ReNeuron has started the placebo-controlled Phase IIb trial in chronic stroke disability with data expected in early 2020. ReNeuron also has the hRPC (human retinal progenitor cells) program for retinitis pigmentosa (currently in Phase I/II) and will also be starting a Phase IIa trial in cone-rod dystrophy. The exosome platform (generated from the CTX cell line) is a further source of products and business development for ReNeuron.

**INDUSTRY OUTLOOK**

Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering.

Y/E Mar	Revenue (£m)	EBITDA (£m)	PBT (£m)	EPS (p)	P/E (x)	P/CF (x)
2017	0.9	(19.8)	(18.2)	(0.49)	N/A	N/A
2018	0.9	(20.2)	(21.0)	(55.66)	N/A	N/A
2019e	0.0	(23.6)	(22.0)	(55.17)	N/A	N/A
2020e	0.0	(27.2)	(27.2)	(70.94)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €18.10  
 Market cap: €1015m  
 Market: Madrid Stock Exchange

**Share price graph (€)**

**Company description**

Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company involved in the development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs with a particular expertise in low molecular weight heparin (LMWH).

**Price performance**

%	1m	3m	12m
Actual	(2.9)	0.6	11.7
Relative*	(5.9)	0.0	19.0

\* % Relative to local index

**Analyst**

Dr Susie Jana

## ROVI Laboratorios Farmaceuticos (ROVI)

**INVESTMENT SUMMARY**

ROVI, a profitable, speciality healthcare company, markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic Spanish market. ROVI is at a major inflection point since obtaining market authorisation for its internally developed enoxaparin biosimilar in 21 European countries (ahead of any competition). During 2018, ROVI commenced marketing in several European countries and has signed out-licensing agreements that cover 63 countries globally - key drivers for sales and operating growth in the medium term. R&D progress continues with its proprietary ISM technology, notably with Risperidone ISM or DORIA, a long-acting injectable for schizophrenia, is expected to complete a Phase III study (PRISMA-3) in Q219.

**INDUSTRY OUTLOOK**

ROVI has a strong presence in the Spanish heparin market (and select international markets through partners), where it has been manufacturing and marketing its flagship product, Hibor (second-generation LMWH), since 1998.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	265.2	39.3	30.3	58.11	31.1	38.6
2017	275.6	30.5	20.3	39.99	45.3	31.2
2018e	299.3	27.5	17.5	31.75	57.0	20.8
2019e	322.0	35.8	26.2	47.37	38.2	53.1



**Sector: Pharma & healthcare**

Price: 57.00PLN  
 Market cap: PLN910m  
 Market: Warsaw Stock Exchange

**Share price graph (PLN)**

**Company description**

Selvita is an R&D and drug discovery services company. It operates two main business units: Innovations Platform (internal R&D pipeline) and Research Services (medicinal chemistry/biology, biochemistry).

**Price performance**

%	1m	3m	12m
Actual	9.8	7.6	(6.7)
Relative*	10.1	1.3	(3.3)

\* % Relative to local index

**Analyst**

Dr Jonas Pecilius

## Selvita (SLV)

**INVESTMENT SUMMARY**

Selvita is an R&D and drug discovery services company. Total sales in Q318 were PLN 56.6m (an increase of 17% from Q317), with 85% of revenue coming from the services segment. In R&D, Selvita out-licensed its lead drug SEL24's to Menarini in March 2017 with a total potential value of the deal of €89.1m. SEL24 is a dual PIM/FLT3 inhibitor in Phase I/II for AML and the first such compound to progress to Phase I/II, to our knowledge. Second lead product is SEL 120, a CDK8 inhibitor, partnered with the Leukemia & Lymphoma Society for AML and is undergoing IND-enabling studies. Multiple collaborations signed with partners such as Merck KGaA, H3 Biomedicine (Eisai) and JV (Nodthera) with Epidarex Capital validate Selvita's research capabilities. As of 30 September 2018, Selvita had PLN 104.7m in cash and other monetary assets.

**INDUSTRY OUTLOOK**

The profiles of SEL24 and SEL 120 are potentially unique when compared to existing clinical-stage competitors and both candidates may offer efficacy advantages. Contract research is a fiercely competitive, but still rapidly growing market and we believe Selvita's geographical location and lower cost benefits make it well placed to compete.

Y/E Dec	Revenue (PLNm)	EBITDA (PLNm)	PBT (PLNm)	EPS (gr)	P/E (x)	P/CF (x)
2016	66.7	8.3	4.6	63.82	89.3	N/A
2017	105.9	18.5	10.2	50.76	112.3	76.6
2018e	104.7	(8.8)	5.9	11.61	491.0	N/A
2019e	119.9	(11.4)	(15.8)	(98.79)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$0.53  
 Market cap: US\$32m  
 Market: NASDAQ

**Share price graph (US\$)**

**Company description**

Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.

**Price performance**

%	1m	3m	12m
Actual	(22.1)	(57.7)	(91.2)
Relative*	(26.8)	(58.4)	(91.4)

\* % Relative to local index

**Analyst**

Dr Nathaniel Calloway

## Sunesis Pharmaceuticals (SNSS)

**INVESTMENT SUMMARY**

Sunesis is a pharmaceutical company developing small molecule oncology drugs. Its lead programme is vecabrutinib, a novel non-covalent, oral BTK inhibitor that may work in Imbruvica relapsed and refractory patients. Data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice-a-day dosing. The programme is in a dose escalation Phase Ib/II trial. It has also developed TAK-580 with partner Takeda, and the preclinical PDK1 inhibitor SNS-510.

**INDUSTRY OUTLOOK**

Sunesis is an oncology company with an early stage asset with a validated target targeting patients that are in B-cell malignancies.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	2.5	(36.3)	(38.0)	(242.37)	N/A	N/A
2017	0.7	(34.4)	(35.5)	(144.63)	N/A	N/A
2018e	0.2	(27.5)	(28.3)	(79.53)	N/A	N/A
2019e	0.0	(30.4)	(31.1)	(48.97)	N/A	N/A

Sector: Pharma & healthcare

Price: ¥192.00  
 Market cap: ¥15821m  
 Market: Tokyo

Share price graph (¥)



Company description

SymBio is a Japanese specialty pharma company with a focus on oncology and haematology. Treakisym is SymBio's branded formulation of bendamustine HCl. Rigosertib was in-licensed from Onconova.

Price performance

%	1m	3m	12m
Actual	(9.0)	(5.0)	(5.9)
Relative*	(11.0)	(1.2)	2.6

\* % Relative to local index

Analyst

Dr Dennis Hulme

## Symbio Pharmaceuticals (4582)

INVESTMENT SUMMARY

SymBio is a speciality pharma focused on Asia-Pacific markets, and has in-licensed two orphan blood cancer products. Treakisym i.v. was approved for r/r low grade NHL/MCL in 2010 and in 2016 received approvals in CLL and first-line low grade NHL/MCL; these new approvals saw in-market Treakisym sales increase by 12% in 2018, following 61% growth in 2017 (NHI price basis). SymBio has in-licensed liquid formulations for injection that will provide Treakisym with patent protection to 2031; a clinical trial is underway of the rapid-infusion liquid formulation which would reduce Treakisym infusion time from 60 minutes to 10 minutes. A Phase III trial of Treakisym in r/r diffuse large B-cell lymphoma is underway. Rigosertib i.v. is in development for r/r higher-risk myelodysplastic syndromes (HR-MDS) and is in a pivotal Phase III global study in 360 patients; SymBio is enrolling patients in Japan and is aiming for potential filing in 2021. SymBio intends to participate in a planned global trial of high-dose oral rigosertib in untreated HR-MDS.

INDUSTRY OUTLOOK

SymBio is focused on in-licensing niche opportunities in hard-to-treat indications often overlooked by big pharma. An in-house screening process to select additional pipeline candidates for development and commercialisation will be key to driving operating leverage.

Y/E Dec	Revenue (¥m)	EBITDA (¥m)	PBT (¥m)	EPS (¥)	P/E (x)	P/CF (x)
2016	2368.0	(2101.0)	(2317.0)	(59.0)	N/A	N/A
2017	3444.0	(3917.0)	(3977.0)	(79.8)	N/A	N/A
2018e	4203.0	(3004.0)	(3030.0)	(46.0)	N/A	N/A
2019e	4325.0	(3591.0)	(3617.0)	(46.5)	N/A	N/A

Sector: Pharma & healthcare

Price: NOK8.22  
 Market cap: NOK433m  
 Market: Oslo

Share price graph (NOK)



Company description

Targovax is an immuno-oncology company headquartered in Oslo, Norway, with two technology platforms that are being developed in a number of oncological indications. ONCOS-102 is an oncolytic virus technology. TG is a therapeutic cancer vaccine platform comprising of peptides mimicking the most common RAS oncogenic mutations.

Price performance

%	1m	3m	12m
Actual	(2.1)	11.4	(50.0)
Relative*	(4.7)	11.5	(52.3)

\* % Relative to local index

Analyst

Dr Jonas Pecuilis

## Targovax (TRVX)

INVESTMENT SUMMARY

Targovax is an immuno-oncology (IO) company specialising in two distinct, but complementary immune activator approaches. Targovax's core proposition is to use its products as immune response primers and combine with other anticancer therapies, such as checkpoint inhibitors, for increased efficacy. ONCOS-102 is a genetically engineered adenovirus being tested in advanced melanoma, mesothelioma, peritoneal malignancies and prostate cancer. The next ONCOS-102 data is expected in H119 (Phase I melanoma), and H120 (Phase I/II mesothelioma). Targovax has also been developing two mutant RAS-specific neo-antigen vaccines from its TG platform. Phase 1b data on TG02 in colorectal cancer and new 3 year data on TG01 in pancreatic cancer are expected in H119. Targovax is exploring options for further development of TG01 including collaborations. We are updating our estimates following Targovax's Q418 results.

INDUSTRY OUTLOOK

Checkpoint inhibitors (CPIs) gained popularity over the past several years, however, a large proportion of patients do not respond to CPIs. Both Targovax's platform technologies are designed to prime immune response to cancers, which offers synergies for use in combination with other immuno-oncology therapies.

Y/E Dec	Revenue (NOKm)	EBITDA (NOKm)	PBT (NOKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2016	0.0	(119.2)	(122.7)	(354.65)	N/A	N/A
2017	0.0	(119.6)	(122.3)	(258.06)	N/A	N/A
2018e	N/A	N/A	N/A	N/A	N/A	N/A
2019e	N/A	N/A	N/A	N/A	N/A	N/A

**Sector: Pharma & healthcare**

Price: A\$0.73  
 Market cap: A\$110m  
 Market: ASX

**Share price graph (A\$)**



**Company description**

Telix Pharmaceuticals is a Melbourne-headquartered global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly targeted radiation.

**Price performance**

%	1m	3m	12m
Actual	(1.4)	(2.0)	40.4
Relative*	(5.8)	(7.2)	37.2

\* % Relative to local index

**Analyst**

Dr Dennis Hulme

## Telix Pharmaceuticals (TLX)

**INVESTMENT SUMMARY**

Telix has assembled a portfolio of molecularly targeted radiation therapeutic and imaging products for kidney, prostate and brain cancers. Each product has been validated by clinical studies or compassionate use, reducing development risk. It has acquired its JV partner ANMI in December, giving it full global rights to the illumet investigational prostate cancer imaging kit. It is already commercialising illumet in the US, including through Cardinal Health, and is developing plans for a pivotal study to allow full approval. It has initiated the ZIRCON confirmatory Phase III for kidney cancer imaging agent TLX250; data due H219. The IPAX-1 Phase I/II study of TLX101 therapy in GBM (brain cancer) commenced recruitment in October and is expected to read out in H219. Telix plans to progress TLX591 therapy into Phase III in chemo-naive prostate cancer in H219/H120.

**INDUSTRY OUTLOOK**

Big pharma has shown keen interest in MTR products. In 2017 Novartis acquired Advanced Accelerator Applications, the developer of the MTR therapeutic Lutathera, for US\$3.9bn. In 2014 Bayer acquired Algeta for ~US\$2.6bn; Algeta had developed Xofigo, a therapeutic radiopharmaceutical for prostate cancer. In December Novartis acquired prostate cancer radiopharmaceutical developer Endocyte for US\$2.1bn.

Y/E Dec	Revenue (A\$m)	EBITDA (A\$m)	PBT (A\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	N/A	N/A	N/A	N/A	N/A	N/A
2017	0.4	(6.4)	(6.4)	(4.98)	N/A	N/A
2018e	5.0	(13.0)	(12.7)	(6.21)	N/A	N/A
2019e	8.4	(17.8)	(17.7)	(8.33)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$4.13  
 Market cap: US\$4m  
 Market: NASDAQ, TASE

**Share price graph (US\$)**



**Company description**

Therapix Biosciences is an Israeli pharmaceutical company developing two cannabinoids to treat Tourette syndrome and mild cognitive impairment. It is currently in Phase IIa and soon to begin Phase I, respectively, and owns or licenses several IPs for cannabinoid nasal and sublingual administration.

**Price performance**

%	1m	3m	12m
Actual	9.5	(51.0)	(22.5)
Relative*	3.0	(51.8)	(23.8)

\* % Relative to local index

**Analyst**

Maxim Jacobs

## Therapix Biosciences (TRPX)

**INVESTMENT SUMMARY**

Therapix is investigating the potential of new formulations of cannabinoids to address underserved diseases of the brain. Therapix recently announced the results of its Phase IIa study of THX-110 for the treatment of Tourette syndrome (TS). The study showed a statistically significant (p=0.002) reduction in tic severity of 21%. The company has also initiated a Phase IIa for obstructive sleep apnea (OSA) and is beginning a Phase IIa for low back pain.

**INDUSTRY OUTLOOK**

Diseases of the brain are a major unmet medical need with few effective or approved therapies for a host of diseases. Cannabinoids have had promising data in many indications in the area and is a class that has received a lot of interest.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2015	N/A	N/A	N/A	N/A	N/A	N/A
2016	0.0	(1.7)	(1.7)	(179.9)	N/A	N/A
2017e	0.0	(4.0)	(4.3)	(118.4)	N/A	N/A
2018e	0.0	(7.7)	(7.7)	(200.1)	N/A	N/A

**Sector: Pharma & healthcare**

Price: €2.77  
 Market cap: €173m  
 Market: Euronext Paris

**Share price graph (€)**

**Company description**

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

**Price performance**

%	1m	3m	12m
Actual	(4.5)	(7.7)	(13.2)
Relative*	(10.9)	(9.1)	(11.0)

\* % Relative to local index

**Analyst**

Dr Daniel Wilkinson

## Transgene (TNG)

**INVESTMENT SUMMARY**

Transgene is developing viral vector-based immunotherapies for combination therapies in oncology and infectious diseases. The company is running multiple clinical trials, including a Phase 2 trial combining TG4010 with Opdivo and chemotherapy in 1L NSCLC, and a Phase 1b/2 trial with Pexa-Vec+Opdivo in 1L advanced liver cancer. Transgene and partner SillaJen are running a global 600-patient Phase 3 study (PHOCUS) for Pexa-Vec+sorafenib in advanced liver cancer. Next-generation platforms Invir.IO and myvac continue to progress, with assets from both expected to enter the clinic in 2019. Gross cash and short-term investments at 30 September were €26.6m. Transgene also has the potential to monetise \$48m in Tasly Biopharmaceuticals shares, received in August for the sale of full Greater China rights to T6002 and T1050.

**INDUSTRY OUTLOOK**

Immunotherapies are among the most promising class of products for cancer. Increased attention is now being paid to the use of combination therapy approaches to improve cancer response rates further.

Y/E Dec	Revenue (€m)	EBITDA (€m)	PBT (€m)	EPS (c)	P/E (x)	P/CF (x)
2016	10.3	(20.4)	(23.1)	(42.9)	N/A	N/A
2017	8.1	(26.4)	(35.0)	(52.0)	N/A	N/A
2018e	7.2	(28.4)	(36.8)	16.1	17.2	N/A
2019e	7.9	(31.1)	(33.8)	(54.5)	N/A	N/A

**Sector: Pharma & healthcare**

Price: US\$2.88  
 Market cap: US\$102m  
 Market: NYSE MKT

**Share price graph (US\$)**

**Company description**

VolitionRx is a Belgium-based diagnostics company focused on developing blood-based cancer diagnostics based on its proprietary Nu.Q™ technology. Its lead program is in colorectal cancer, which entered the European market in 2017.

**Price performance**

%	1m	3m	12m
Actual	24.7	22.6	(3.0)
Relative*	17.3	20.5	(4.6)

\* % Relative to local index

**Analyst**

Dr Jonas Pecuilis

## VolitionRx (VNRX)

**INVESTMENT SUMMARY**

VolitionRx's proprietary Nu.Q™ technology detects the level and structure of nucleosomes in the blood using one drop of blood serum. It is currently focused on colorectal cancer (CRC), a very large opportunity with around 225 million people eligible for screening (US/EU). VolitionRx will be participating in a 13,500 undiagnosed person trial in the US to gain FDA approval for front-line CRC screening. For Europe, the company plans to market a triage screening test followed by a front-line screening test. Readouts from 4,300 and 12,000+ sample studies are expected in H218 and Q119 respectively to support a CE Mark. Volition recently announced positive data from a pancreatic cancer study with Nu.Q™. Volition also recently secured new funding: \$9m private placement, \$8.4m (gross) through a registered public offering of common shares and \$700k from the Walloon Regional Government. Volition's new partner Active Motif will begin to sell Nu.Q™ assay research kits which Volition hope will help to validate the assays and explore new indications.

**INDUSTRY OUTLOOK**

The blood-based cancer screening market is in its nascent stages with great potential and serves an unmet medical need. Currently there are few, if any, non-invasive screening methods for the vast majority of cancers.

Y/E Dec	Revenue (US\$m)	EBITDA (US\$m)	PBT (US\$m)	EPS (c)	P/E (x)	P/CF (x)
2016	0.0	(12.4)	(12.5)	(54.02)	N/A	N/A
2017	0.0	(15.0)	(15.1)	(57.29)	N/A	N/A
2018e	0.1	(17.7)	(17.8)	(48.50)	N/A	N/A
2019e	1.4	(16.9)	(16.9)	(44.27)	N/A	N/A

Sector: Pharma & healthcare

Price: SEK42.90  
Market cap: SEK272m  
Market NASDAQ OMX First North

#### Share price graph (SEK)



#### Company description

Xbrane Biopharma is a Swedish developer of biosimilar products. The lead product is Xlucane, a Lucentis biosimilar partnered with STADA and produced using an efficient manufacturing system. A triptorelin generic, Spherotide, is being sold in Iran.

#### Price performance

%	1m	3m	12m
Actual	(8.9)	(7.7)	(39.3)
Relative*	(15.4)	(13.5)	(41.9)

\* % Relative to local index

#### Analyst

Dr John Savin

## Xbrane Biopharma (XBRANE)

#### INVESTMENT SUMMARY

Xbrane now focuses on developing high-margin biosimilar products. In July Xbrane did a deal with STADA on Xlucane, its Lucentis biosimilar, and gained an upfront fee of a €7.5m; management estimates that Xbrane's 50:50 profit share could be worth up to €100m per year. STADA will market Xlucane. Xbrane aims to start clinical development in Q119 targeting a 2022 launch. The FDA has accepted Xbrane's IND application for initiation of the Xplore trial, a Phase III US trial with Xlucane. In drug delivery, Iranian bulk sales of one-month Spherotide (triptorelin) appear level at SEK25m a year. In Europe, the key market, Spherotide development needs a partner; the key three-month depot will follow a year later. FY18 results are on 28 February.

#### INDUSTRY OUTLOOK

Roche/Novartis 2017 sales of Lucentis were \$3.3bn. There are two other biosimilars in late development, one from bioeq (with Formycon) and one from Samsung Bioepis. In triptorelin, Ipsen, the market leader, had sales of €348.7m in 2017 with 3.6% growth.

Y/E Dec	Revenue (SEKm)	EBITDA (SEKm)	PBT (SEKm)	EPS (fd) (öre)	P/E (x)	P/CF (x)
2016	0.0	0.0	(25.1)	(552.0)	N/A	N/A
2017	20.8	(40.9)	(44.2)	(814.0)	N/A	N/A
2018e	22.2	0.9	(3.4)	(58.0)	N/A	16.3
2019e	25.0	(176.6)	(182.2)	(2881.0)	N/A	N/A



## Company coverage

Company	Note	Date published
<a href="#">Acacia Pharma</a>	Update; Flash	07/11/2018; 07/12/2018
<a href="#">Acarix</a>	Update; Update	17/09/2018; 28/11/2018
<a href="#">ADL Bionatur Solutions</a>	Initiation	10/12/2018
<a href="#">AFT Pharmaceuticals</a>	Update; Update	30/05/2018; 30/11/2018
<a href="#">ASIT biotech</a>	Update; Update	20/11/2018; 17/01/2019
<a href="#">Atossa Genetics</a>	Update; Outlook	15/06/2018; 07/12/2018
<a href="#">Auris Medical Holding</a>	Initiation; Update	01/11/2018; 19/11/2018
<a href="#">Basilea Pharmaceutica</a>	Update; Update	21/08/2018; 10/01/2019
<a href="#">BioPorto Diagnostics</a>	Update; Update	03/10/2018; 09/10/2018
<a href="#">BONESUPPORT</a>	Update; Update	03/08/2018; 16/11/2018
<a href="#">Brighter</a>	Initiation	25/09/2018
<a href="#">Cantargia</a>	Update; Update	30/10/2018; 03/01/2019
<a href="#">Carmat</a>	Update; Update	21/12/2017; 26/10/2018
<a href="#">CASI Pharmaceuticals</a>	Initiation; Update	29/11/2018; 10/12/2018
<a href="#">Cellular Biomedicine Group</a>	Update; Update	04/04/2018; 05/10/2018
<a href="#">Celyad</a>	Update; Update	03/12/2018; 07/12/2018
<a href="#">Clal Biotechnology Industries</a>	Update; Update	23/08/2018; 03/12/2018
<a href="#">Deinove</a>	Outlook; Update	01/09/2017; 23/10/2017
<a href="#">Destiny Pharma</a>	Update; Flash	01/10/2018; 25/01/2019
<a href="#">e-Therapeutics</a>	Update; Outlook	06/12/2018; 12/12/2018
<a href="#">Elbit Medical Technologies</a>	Update; Update	06/09/2018; 06/12/2018
<a href="#">Herantis Pharma</a>	Initiation	20/09/2018
<a href="#">Hutchison China Meditech</a>	Update; Update	20/08/2018; 18/09/2018
<a href="#">Immunicum</a>	Update; Update	09/11/2018; 19/11/2018
<a href="#">Immunovia</a>	Outlook; Update	22/03/2018; 06/09/2018
<a href="#">Immutep</a>	Update; ADR Update	21/11/2018; 22/11/2018
<a href="#">InMed Pharmaceuticals</a>	Update; Update	20/11/2018; 14/02/2019
<a href="#">International Stem Cell</a>	Update; Update	20/08/2018; 04/12/2018
<a href="#">Kazia Therapeutics</a>	ADR Update; Update	29/10/2018; 29/10/2018
<a href="#">MagForce</a>	QuickView; Update	19/11/2018; 21/11/2018
<a href="#">Medigene</a>	QuickView; Update	19/11/2018; 04/01/2019
<a href="#">Mesoblast</a>	Update; Update	07/06/2017; 07/11/2017
<a href="#">MGC Pharmaceuticals</a>	Initiation	22/10/2018
<a href="#">Mologen</a>	QuickView; Update	19/11/2018; 04/01/2019
<a href="#">NetScientific</a>	Update; Update	24/10/2018; 30/11/2018
<a href="#">NeuroVive Pharmaceutical</a>	Outlook; Update	05/10/2018; 17/12/2018
<a href="#">Newron Pharmaceuticals</a>	Update; QuickView	11/10/2018; 19/11/2018
<a href="#">Nuevolution</a>	Update; Update	25/09/2018; 10/12/2018
<a href="#">Oncology Venture</a>	Update; Update	21/12/2018; 13/02/2019
<a href="#">Onxeo</a>	Update; Update	27/04/2018; 27/11/2018
<a href="#">Orexo</a>	Update; Outlook	17/12/2018; 12/02/2019
<a href="#">Oryzon Genomics</a>	Outlook; Update	18/07/2018; 09/11/2018
<a href="#">OSE Immunotherapeutics</a>	Initiation	06/12/2018
<a href="#">Oxford BioMedica</a>	Update; Update	08/06/2018; 09/11/2018
<a href="#">Pacific Edge</a>	Update; Update	04/06/2018; 07/01/2019
<a href="#">Paion</a>	Update; QuickView	12/11/2018; 19/11/2018

<a href="#">PDL BioPharma</a>	Update; Update	16/08/2018; 13/11/2018
<a href="#">Photocure</a>	Update; Update	16/08/2018; 22/11/2018
<a href="#">Pixium Vision</a>	Flash; Update	11/01/2019; 19/02/2019
<a href="#">Quantum Genomics</a>	Update; Update	09/10/2018; 13/11/2018
<a href="#">Redhill Biopharma</a>	Update; Update	02/10/2018; 19/12/2018
<a href="#">Regeneus</a>	Outlook; Update	29/04/2018; 04/09/2018
<a href="#">ReNeuron Group</a>	Flash; Flash	04/01/2019; 24/01/2019
<a href="#">ROVI Laboratorios Farmaceuticos</a>	Update; Update	30/07/2018; 14/11/2018
<a href="#">Selvita</a>	Update; Outlook	29/06/2018; 18/01/2019
<a href="#">Sunesis Pharmaceuticals</a>	Update; Update	10/12/2018; 07/02/2019
<a href="#">SymBio Pharmaceuticals</a>	Update; ADR Update	07/12/2018; 12/12/2018
<a href="#">Targovax</a>	Update; Update	13/06/2018; 21/11/2018
<a href="#">Telix Pharmaceuticals</a>	Initiation; Update	20/08/2018; 31/10/2018
<a href="#">Therapix Biosciences</a>	Update; Update	18/08/2017; 17/11/2017
<a href="#">Transgene</a>	QuickView; Update	19/11/2018; 30/11/2018
<a href="#">VolitionRx</a>	Update; Update	18/07/2018; 29/11/2018
<a href="#">Xbrane Biopharma</a>	Update; Outlook	01/03/2017; 23/11/2018

---

## General disclaimer and copyright

This report has been prepared and issued by Edison. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) followed by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

**Copyright:** Copyright 2018 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

---

## Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

## New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

## United Kingdom

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

## United States

The Investment Research is a publication distributed in the United States by Edison Investment Research, Inc. Edison Investment Research, Inc. is registered as an investment adviser with the Securities and Exchange Commission. Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a) (11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076960  
Schumannstrasse 34b  
60325 Frankfurt  
Germany

London +44 (0)20 3077 5700  
280 High Holborn  
London, WC1V 7EE  
United Kingdom

New York +1 646 653 7026  
1,185 Avenue of the Americas,  
3rd Floor, New York, NY 10036  
United States of America

Sydney +61 (0)2 8249 8342  
Level 12, Office 1205, 95 Pitt St,  
Sydney NSW 2000  
Australia